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ABSTRACT 
Background 
The World Health Organisation estimates that more than 50% of medicines are inappropriately 
used globally. The situation is worst in developing countries such as Nigeria, where irrational 
prescribing practices account for wastage of resources, catastrophic medicines costs and poor 
access to health services. In 2005, the Social Health Insurance Programme was launched as a 
financially sustainable model to achieve cost effective and affordable health care services 
including medicines. This study investigated prescribing practices and availability of medicines 
in the Social Health Insurance Programme in accredited public sector secondary hospitals in 
the Federal Capital Territory, Nigeria.  
Methodology 
The study is a descriptive, cross-sectional and retrospective survey of prescriptions of insured 
outpatients in the Federal Capital Territory, Nigeria. Four hospitals were selected by 
stratification of thirteen (13) public secondary hospitals in the territory into urban/peri-urban 
areas, followed by random selection of two hospitals from each stratum.  
A total of seven hundred and twenty (720) retrospective prescription encounters of insured 
outpatients were systematically selected from encounters between July 2009 and June 2010 at 
the selected facilities. Data on prescribing practices and the extent to which prescribed 
medicines were provided were assessed with the use of modified WHO/INRUD indicators. 
Descriptive statistics were generated with Epi-info (version 3.4.3) and SPSS (version 17.0) 
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Results  
Out of the seven hundred and twenty (720) prescriptions that were assessed analgesics/NSAID, 
antibiotics, antimalarials and haematinics/vitamins collectively accounted for 67.4% of the 
medicines prescribed. 
A comparison of the results with WHO/Derived reference values showed that average number 
of medicines prescribed per prescription (3.5 ±1, p<0.001) and the rate of antibiotic prescribing 
(53.7%, p=0.009) were higher than the WHO recommended ranges of (1.6-1.8) and (20.0- 
25.4%) respectively.  
The use of generic names in prescribing (50.9%, p<0.0009) and medicines prescribed from the 
Essential Medicine List (74.2%, p=0.05) were considerably lower than the standard (100%)  
However, the rate of injection prescribing (12.49%, p=0.4) was within the recommended range 
(10.1–17.0%). 
The study also found that 85.1%, (p=0.001) of prescribed medicines were dispensed, while 
93.4% (p=0.256) of essential medicines were dispensed which was lower than the 
recommended standard (100%). Overall, only 58%,(p<0.0001) of patients had all prescribed 
medicines completely dispensed and this was significantly lower than the desired standard 
(100%.) in social health insurance programmes. 
Conclusions 
The findings of this study show trends toward irrational prescribing practices as characterized 
by poly-pharmacy, overuse of antibiotics, sub-optimal generic prescribing, as well as poor 
adherence to the use of NHIS-Essential Medicine List. There was sub-optimal provision of 
prescribed medicines. These are potential threats to the scheme‟s goal of universal access to 
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health care in the year 2015. Pragmatic multi-component interventions are recommended to 
promote rational prescribing and improve equity in access to essential medicines. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Background  
The World Health Organisation (WHO) estimates that more than half of all medicines are used 
irrationally (WHO, 2004a, WHO). The situation is worst in resource constrained countries where 
irrational prescribing practices account for more than 50% of wastage in health facilities (Quick, 
2003; Holloway, 2004, WHO, 2009a; 2010a).  
Rational use of medicines requires that “patients receive quality medicines, appropriate to their 
clinical needs, in doses that meet their individual requirements, for an adequate period of time 
and at the lowest cost to them and the community” (WHO, 1985). The objectives of rational use 
of medicines are to ensure safety, cost-effectiveness and the maximization of the potential values 
of medicines in the provision of universal access to health care (WHO, 2004b).  
Irrational prescribing occurs when prescription patterns are not in conformity with WHO 
definition of rational prescribing given above. For example, the prescribing of too many 
medicines per patient and the failure to prescribe in accordance with clinical guidelines often 
result in widespread health hazards and shortages of medicines in health facilities (WHO, 2002; 
2004a; 2009a). The financial cost incurred as a result of irrational prescribing disproportionately 
affects the population who also spend the largest proportion of their household income as out of 
pocket expenditures on prescribed medicines (Faden, et al., 2011). 
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In Nigeria and other developing countries, poor and vulnerable people who constitute the 
majority in the population are often the hardest hit as they have to contend with either paying 
high costs for their medicines and deepening their impoverishment, or suffer catastrophic health 
consequences resulting from financial barriers to accessing prescribed medicines (Hogerzeil, 
2004; Soyibo, et al., 2005; Aina, Tayo and Taylor, 2008; Faden, et al., 2011). 
Over the past few decades, the Federal Government identified problems of inadequate funding 
and irrational use of available resources as access barriers to health services and consequently 
introduced several strategies including the EML, the Bamako Initiative (BI) and rhe National 
Medicine Policy to facilitate equitable and sustainable access to medicines. 
The EML comprises of a limited range of medicines, selected on the basis of safety, efficacy and 
cost-effectiveness in treating prevailing health problems in the population. It was introduced in 
1986 with the aim of promoting the use of affordable medicines that meet the health needs of the 
population in order to contain the escalating cost of health care (FMOH, 2003). In 1987, African 
Ministers of Health resolved in Bamako to improve the health outcome of their populations 
through sustainable financing of access to quality health care programmes by the process of 
community participation in funding and managing supplies of essential medicines. The concept, 
also known as the BI is based on the principle that sustainable availability and accessibility of 
basic essential generic medicines can be achieved by ensuring a steady supply of affordable 
medicines through the institutionalization of out-of-pocket payments and the medicine-revolving 
programme. Following the resolution, the Federal Government of Nigeria instituted this initiative 
in all the public health facilities across the country (Omoruan, Bamidele and Philips, 2009). 
Subsequent to this, the National Medicine Policy was introduced in 1990 to provide the 
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framework for ensuring availability of effective, affordable, safe and quality  medicines at all 
times in all sectors of the health system (FMOH, 2004a).   
However, despite these policies, access to health care services by the poor was compromised by 
several factors including over-prescribing and excessive use of costly medicines, which 
invariably escalate the costs of health services beyond the reach of the poor (Adeyi and Wouters, 
1996; Uzochukwu, Onwujekwe and Akpala, 2002; Ogunbekun, Liu, 2003; Akande and Ologe, 
2007). 
In response to the recurrent problems of poor funding of health services and inappropriate use of 
available resources, the National Health Insurance Scheme (NHIS) was introduced in Nigeria in 
June 2005 as a financially sustainable model to address a number of challenges plaguing the 
health system, and to guarantee universal access to health care services, including medicines 
(Lecky, 2004).  
Acknowledging the importance of medicines as a major component of health care services, the 
scheme adopted the essential medicines concept as the most effective tool in ensuring rational 
prescribing, availability of medicines and equitable access to affordable medicines (WHO, 
2003a; Hogerzeil, 2004). The essential medicines concept requires that the medicines listed in 
the EMLand recommended in the standard treatment guidelines should be the basis for 
prescribing and reimbursement of fees for services rendered (WHO, 2004b; 2008). Recognising 
that unnecessary use of services will affect the solvency and the sustainability of the scheme, the 
government clearly enunciated its policy for promoting rational prescribing by providing the 
NHIS with Operational Guidelines, an Essential Medicines/Price List and Standard Treatment 
and Referral Protocols. The scheme also recommended regular monitoring and audit of service 
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utilization to measure access and quality of health care services, including essential medicines 
(FMOH, 2005) 
However, six years after the inception of the scheme, access to essential medicines remains a 
challenge with numerous reports of poor utilization of the EML (Leo and Okafor, 2012),  
inadequate provision of prescribed medicines and payments for services covered in the scheme 
(Sanusi and Awe, 2009). Deviations from combination of WHO and local standards  standards 
for prescribing and patient care, shown in Table 1.1 are often cited as key factors contributing to 
poor access to prescribed medicines in public sector hospitals (WHO, 2004a; b).  
Table 1.1: WHO/Reference Values for Prescribing and Patient Care (Medicines Dispensed) 
Indicators 
 
 
 
 
 
 
 
 
 (WHO, 2004a: Isah , Quick, Mabadeje , Santoso and Hogerzeil, 2002) 
A number of studies had been conducted to assess the NHIS programmes in the context of 
enrollment and service utilization rates. Akande, Salaudeen and Babatunde (2011) reported an 
increase in the utilization of health services in terms of the number of cases seen after 
Indicators Values Type 
Average No. of Medicines prescribed 1.6 - 1.8 Derived standard    
% of Prescription encounters with an 
antibiotic prescribed. 
20.0 – 25.4 %   Derived standard   
% of Prescription encounters with an 
injection prescribed 
10.1 – 17.0%   Derived standard   
% of Medicines prescribed by generic name. 100% WHO standard 
% of Medicines prescribed on   EML  100% WHO standard 
% of Medicines actually dispensed 100% WHO standard 
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commencement of the scheme. Agba, Ushie and Osuchukwu (2010) investigated the impact of 
the NHIS on employees‟ access to health care services in Cross River State, Nigeria. However, 
the existing prescribing practices and the capacity of accredited health facilities in ensuring 
availability and equity of access to essential medicines have not been determined. These need to 
be investigated seeing that they are fundamental determinants of universal access to health care 
and key factors in assessing health system performance.  
This study was carried out to assess the prescribing practices and the extent to which prescribed 
essential medicines are available to insured patients, with the aim of providing relevant data 
needed for identification of areas where rational and evidence-based interventions could guide 
future planning and improve management of the programme.  
1.2 Country Profile  
1.2.1 Demographic parameters 
Nigeria is located on the West Coast of Africa, covering a land mass of 923,768 square 
kilometers.  The country has an estimated population of 140 million and an annual growth rate of 
3.2%, thereby making it the most populous African country (NPC, 2009). Nigeria is made up of 
36 states and a Federal Capital Territory which are subdivided into local governments and areas 
councils respectively. About 55% of the population lives in the rural areas (NPC, 2009). 
1.2.2 Health Status Indicators  
According to the Federal Ministry of Health, Nigeria‟s health status indicators are among the 
worst in sub-Saharan Africa (FMOH, 2004b). Infant mortality rate is currently estimated at 138 
deaths per 1,000, (WHO, 2009b). Life expectancy at birth is estimated at 53 years for males and 
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54 years for female, while under-five child mortality is estimated at 197 deaths per 1,000 live 
births. In comparison, life expectancy for Ghana and South Africa were estimated at 55 years 
and 59 years; 50 years and 52 years for males and females respectively, while estimates for 
under-five mortality in Ghana and South Africa are 112 deaths per 1000 and 67 deaths per 1,000 
respectively (Wambebe and Ochekpe, 2011; WHO, 2009b). In the 2000 WHO Health Report 
Nigeria was ranked 187
th
 position out of 191 member states in terms of health system 
performance and health status indicators. The high mortality and morbidity rates associated with 
Nigeria cannot be divorced from its health system (Omoruan, Bamidele and Philips, 2009; 
Sanusi and Awe, 2009).  
Generally, communicable diseases are the major causes of morbidity and mortality in Nigeria. 
According to the FMOH (2010), malaria accounts for 60% of all outpatient cases, 30% of 
admissions in the hospitals and 300,000 deaths annually (FMOH, 2010; Wambebe and Ochekpe, 
2011). The country ranks fourth among tuberculosis-burdened countries and accounts for 3.4 
million out of the 33 million global population of people living with the Human 
Immunodeficiency virus/Acquired immune Deficency Syndrome (HIV/AIDS), making it the 
third after South Africa and India as countries with the highest populations of people living with 
the HIVAIDS virus in the world (UNAIDS, 2008). 
1.2.3 Health Financing 
Prior to the commencement of the NHIS, expenditure on health care was from a variety of 
sources including budgetary allocations from the three tiers of government, health insurance, 
private sector contributions, out-of-pocket expenses, loans and other forms of donations (WHO, 
2009c; Kannegiesser, 2009; Omoruan, Bamidele and Philips, 2009). The health sector allocation 
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as a percentage of budget stood at 4.4% in 2005, 5.6% in 2006 and 7.28% in 2007 (WHO, 
2009c)    
 More recent figures out the total expenditure on health at 5.8 % of the Gross Domestic Product 
(CIA, 2009 estimates) and public expenditure capita for health is less than US$ $ 5 (CIA, 2010 
estimates). These allocations are grossly inadequate when compared to the WHO 
recommendation of US$ $ 34 for developing countries (Omoruan, Bamidele and Philips, 2009; 
Sanusi and Awe, 2009). This resulted in the population paying more than 70% of total health 
expenditure as out-of- pocket payments in 2006 (Kannegiesser, 2009, Omoruan, Bamidele and 
Philips, 2009). The inadequacy in funding of the health sector also contributed to the 
deteriorating public health infrastructure, decline in quantity and quality of service delivery, and 
loss of confidence in public sector health facilities (WHO, 2009c; 2006; Omoruan, Bamidele and 
Philips, 2009).  
 To ensure universal access to good healthcare services and reduce health care costs especially to 
the poor, the Federal Government established the NHIS as an alternative source of health 
financing through equitable distribution of healthcare costs among different income groups 
(Omoruan, Bamidele and Philips, 2009; WHO, 2009c). 
1.3 National Health Insurance Scheme 
Social health insurance is a collective health security system provided by the government that 
guarantees the provision of needed health care services, on the payment of token contributions at 
regular intervals (WHO, 2003b). The NHIS was established under Act 35 of 1999 as the 
corporate apex body for implementation of government goal of providing equitable access to 
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comprehensive quality health care services for Nigerians through various levels of social health 
insurance programmes (Appendix 2).  
The scheme officially commenced in June, 2005 with the launching of its Formal Sector Social 
Health Insurance Programmes (FS-SHIP) for federal civil servants. Participation is mandatory 
for every organisation with ten or more employees. It entails the registration of the enrollee, the 
spouse and up to four biological children under the age of 18years. 
Contributions in the FS-SHIP are earnings-related; it entitles the beneficiaries to equitable 
services in the benefits plan including access to all essential medicines recommended in the 
programme. Enrollees of the Organized Private Sector Social Health Insurance Programme 
(OPS-SHIP) have the option of choosing their preferred level of Health Care Benefits in line 
with their levels of contributions. Beneficiaries may access primary care services in any 
accredited public or private providers however; secondary and tertiary care services are accessed 
through the referral system (FMOH, 2005a). 
Various operators have distinct roles in ensuring the achievements of the goals of the Scheme. 
Enrollees, in addition to their monthly contributions, pay 10% cost of prescriptions as co-
payment and part of risk sharing (FMOH, 2005a). 
Primary Care Providers (PCP) including the outpatient departments in the secondary and tertiary 
hospitals, constitute the first care contacts (i.e. gatekeepers). They provide basic services set out 
in the benefit package including essential medicines covered in the scheme. They also refer all 
procedures which require specialists‟ attention to secondary facilities including pharmacies, 
laboratories, physiotherapies and radiography centres; the tertiary health care providers such as 
the teaching hospitals receive referred cases from the secondary care providers.  
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Generally, the provision of medicines in the scheme is done by accredited pharmacies that are 
required to stock and dispense all generic essential medicines covered in the scheme. 
Payment for services rendered at the primary level of care is in the form of monthly capitation 
made to physicians, which is an advance payment for the services rendered by the physicians, 
cost of medicines and other indirect services including laboratory and x-ray services. By this 
arrangement, the PCPs are required to send out prescriptions to approved pharmacies and make 
payments for the medicines dispensed out of their monthly capitation (FMOH, 2005a).  
On the other hand, the secondary and tertiary hospitals with approved on-site pharmacies are 
required to stock most of the medicines covered in the scheme as well as send out prescriptions 
to approved private pharmacies to ensure all identified out of stock medicines are dispensed to 
patients (FMOH, 2005a). By this arrangement, payment for essential medicines and other 
services rendered at the secondary and tertiary levels of care are settled through reimbursement 
of fees for services (Appendix 3).  
All providers in the scheme are required to maintain standard records in respect of services 
rendered including medicines prescribed and dispensed. 
 
The Health Maintenance Organizations (HMOs) are statutorily empowered to supervise the 
activities of health care providers to ensure conformity with set standards. Their roles also 
include payment of monthly capitation to the PCPs and reimbursement of fees for services to 
secondary and tertiary health providers (FMOHa, 2005). The over-all regulation of the scheme 
rests with the NHIS Council (Awosika, 2005).   
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1.4 Study Setting 
The Federal Capital Territory (FCT), where this study was conducted is located in North central 
part of Nigeria (Fig 1.1).  It occupies a land mass of 8000km
2 
and consists of six area councils 
namely Abaji, Bwari, Gwagwalada, Kuje, Kwali and Abuja Municipal Area Council (AMAC) 
which is the capital of Nigeria (FCT Baseline Data, 2009). 
Following the move of the seat of power from Lagos to Abuja in December 1991, the FCT 
experienced a population growth rate of 20 to 30% per year. According to available information, 
the population now stands at 1.4 million, which is equivalent to 1% of the total population of the 
country (NPC, 2009). The rapid growth exceeded government‟s capacity to accommodate 
everyone within the city. Consequently, area council workers, the poor and low income earners 
who cannot afford the cost of living in the capital city, reside in the peri-urban areas of the 
territory. The peri-urban areas are densely populated and poorly developed in terms of 
infrastructure; this makes their population more susceptible to communicable diseases compared 
with the urban dwellers (Ogunbekun, 1996; FCT Baseline Data, 2009). 
The territory has 434 primary health care centres, several private hospitals, 13 public sector 
secondary hospitals, two public sector tertiary hospitals and over 100 registered pharmacies 
(FCT Health Report, 2006). All the public secondary and tertiary hospitals are participants in the 
health insurance scheme whilst, the primary health centres still need to be accredited to 
participate in the scheme.  
The public sector secondary hospitals are managed by the Health and Human Services 
Secretariat (HHSS) and as at December 2006, the HHSS had 290 medical doctors and 160 
Pharmacists including pharmacy technicians as its staff (FCT Health Report, 2006). The facilities 
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have a large population of health insurance outpatients in attendance. Of the 13 hospitals, AMAC 
has seven with 100-150 patients attending the general outpatient department daily, of whom 10-
20 patients are health insurance outpatients. Each of the remaining five area councils has at least 
one hospital in its satellite towns with 20-40 patients attending the general outpatient department 
daily, of whom 5-10 patients are health insurance outpatients (FCT Health Statistical Bulletin, 
2009).  
Each of the hospitals has an accredited pharmacy department that is dedicated to rendering 
pharmaceutical services to only insured patients. Designated prescription sheets branded NHIS, 
are used for prescribing medicines for all social health insurance patients and duplicates of these 
prescription sheets are kept separately from other prescription sheets in the pharmacy stores. The 
pharmacy departments also ensure that designated logbooks on medicine utilization are kept as 
recommended by the NHIS.  
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Fig. 1.1 Map of FCT area council towns and Abuja city (phase I and II) 
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1.5 Problem Statement 
Studies have found that up to 40% of the health budget of developing countries is spent on 
medicines procurement, and more than half of the procured medicines are wasted through 
irrational prescribing practices which in turn, affect access to health services (MSH, 1997; WHO, 
2004a; b; 2006). Over the past few decades, several cases of irrational use of medicines, over-
prescribing and medicines shortages have been reported in health facilities in Nigeria, in spite of 
the various initiatives designed by the government to promote appropriate prescribing and access 
to essential medicines, particularly in public health facilities (Uzochukwu, Onwujekwe and 
Akpala 2002; Akande and Ologe, 2007).  
Although, the recently adopted NHIS was established with the necessary tools and regulatory 
framework for ensuring rational prescribing and access to essential medicines, findings from 
surveys of health consumers‟ perceptions and newspapers reports have highlighted cases of poor 
quality services, medicine shortages and unofficial payments for services that ought to be 
covered by scheme premiums (Sanusi and Awe, 2009; Okon, 2010; Onyedibe, Goyit  and Nnadi, 
2012). These revelations have generated concerns about the ability of the scheme meeting its 
objectives of providing equitable access to quality and cost-effective medicines to all health 
seeking scheme members. This study was undertaken to provide insights into prescribing 
practices within the scheme, and the extent to which essential medicines are prescribed by health 
providers and dispensed to patients.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.0   Introduction 
Over the past few decades, the WHO and International Network for Rational Use of Medicines 
(INRUD) have collaborated with countries, including Nigeria, to conduct research and formulate 
policies on medicines usage and the development and application of appropriate interventions to 
promote rational use of medicines use (WHO, 2004b; 2008; 2010).  
This chapter defines some concepts underpinning the rational use of medicines with a focus on 
the global problems of irrational prescribing as well as its attendant consequences. The chapter 
also illustrates the prevalence of different forms of irrational prescribing practices in various 
settings and countries, and summarizes the literature on the WHO initiatives for promoting 
rational use of medicines and their effects on availability of medicines and access to cost 
effective quality health care services. 
It concludes by describing the innovative impacts of social health insurance on prescribing 
practices and access to essential medicines in different countries and then describes the NHIS 
framework for ensuring rational prescription, cost containment and availability of prescribed 
medicines in the FS-SHIP in Nigeria. 
2.1 Concept of Rational Use of Medicines 
The current global focus on health-related Millennium Development Goals (MDG) has once 
again brought to the fore the need to promote rational use of medicines and ensure sustainable 
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availability of medicines: in facilitating universal access to quality cost-effective health care 
(WHO, 2004b; 2010b).  
The definition of Rational Use of Medicines emanated from the Conference of Experts in the 
Rational Use of Medicines (ICIUM) held in Nairobi in 1985 (WHO, 1985) and according to 
these experts, the requirements of the rational use of medicines can only be fulfilled, if the 
processes of medicines uses are appropriately followed by prescribers, dispensers and the 
community (Laing, Hogerzeil, and Ross-Degnan, 2001; Brunthland, 2003).  
Rational use of medicines in the context of the prescribers, entails that the prescriber takes the 
necessary steps to make an accurate diagnosis, decide whether medicines treatment is necessary 
or not, select the best available medicines, choose the most appropriate dosage form, prescribe 
the medicine in adequate quantity to the right patients and monitor the treatment (Laing, 
Hogerzeil, and Ross-Degnan, 2001; Brunthland, 2003; Neyaz, et al., 2011). Irrational prescribing 
comprises of practices which are at variance with the WHO criteria for appropriate prescribing 
including the use of medicines when no medicine therapy is indicated, poly-pharmacy or over-
prescription of medicines, overuse or under use of antibiotics and other anti-infective agents, 
indiscriminate use of injections and overuse of multivitamins and tonics for malnutrition. Other 
examples include unnecessary use of expensive medicines, the use of medicines with doubtful or 
unproven efficacy and non-compliance with the National Medicines List of Formulary 
(Greenhalgh, 1987; Laing, 1990; Hogerzeil, Bimo and Laing, 1993; WHO, 2004a).  
2.2          Scope of Irrational Medicines Use 
According to information available from the WHO experts, more than half of all medicines in the 
world are used inappropriately (Greenhalgh, 1987; Laing, 1990; WHO, 2004a). Irrational use of 
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medicines is a global public health problem affecting developed countries including Australia, 
Canada and the USA as well as developing countries including Nigeria, South Africa, Pakistan 
and China (Hogerzeil, 1995; WHO, 2004a; Kumari, et al., 2008; Sun, et al., 2009). 
Unfortunately, the problem is more pronounced in developing and resource-constrained 
countries (WHO, 2004a; b). 
There has been a general misconception that the problem of irrational use of medicines is due to 
inappropriate use by consumers (Greenhalgh, 1987; Hardon and Le Grand 1993). However, a 
review of the literature indicates that inappropriate prescribing of medicines in public and private 
health facilities is the greatest contributor to the global problem of medicine use (Hogerzeil, 
1995; Gupta, et al., 1997; Haldar, et al., 2011). It permeates the three tiers of health care 
primary, secondary and tertiary health facilities (Odunsanya, 2004; WHO, 2004a; Awad, Ball 
and Eltayeb, 2007), both urban and rural areas (Ross and Macleod, 2005; Dutta
 
and Chakraborty, 
2010) and the different categories of physicians, even though Hogerzeil (1995) argued that the 
practice is more frequent with general practitioners.  
2.3     Manifestations of Irrational Prescribing Practices 
Medicine use studies conducted in different parts of the world provide evidence of various forms 
of irrational prescription patterns, including poly-pharmacy, indiscriminate use of antibiotics, 
overuse of injections of injections, unnecessary use of branded medicines and poor use of 
essential medicine lists (WHO, 2004a; 2009c). 
2.3.1 Poly-pharmacy 
Poly-pharmacy is the simultaneous use of multiple medicines per patient. Appropriate 
prescribing requires that patients should be given the medicines needed and the number be kept 
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as low as possible (Pavin, et al., 2003; Laing, Hogerzeil, and Ross-Degnan, 2001). The practice of 
poly-pharmacy is widespread in developing countries as a result of attempts by health personnel 
to treat presumptive diseases without recourse to performing diagnostic test (Uzochukwu et al 
2011).. 
Studies conducted in developing countries have revealed several examples of poly-pharmacy in 
prescription encounters of public health facilities, with some facilities having an average of more 
than 3.0 medicines per prescription encounter. For example, Mohlala,
 
et al., (2010) reported an 
average of 3.2 medicines per prescription in some public facilities in two provinces in South 
Africa.  Kumari, et al., (2008) reported an average of 3.1 medicines per encounter in several 
public health facilities in Lucknow District, India, while Haldar, et al., (2011) reported an 
average of 3.7 medicines per encounter in a survey of prescriptions from four randomly selected 
Central Government Health Scheme dispensaries in Kolkata, India.  
Several studies conducted in Nigeria also revealed the prevalence of poly-pharmacy in 
prescriptions from outpatient departments in health facilities. For example, in a study conducted 
to evaluate the effects of the BI medicine revolving fund on rational use of medicines in Eastern 
Nigeria, Uzochukwu, Onwujekwe and Akpala (2002) reported 5.3 medicines per prescription.  
Akande and Ologe (2007) surveyed the prescription patterns of a secondary public hospital in 
Ilorin, Nigeria, and concluded that poly-pharmacy was prevalent amongst the physicians. The 
report of Enato and Chima (2011) on medicine utilization patterns and patient care practice at the 
Federal Medical Center, Lokoja, in Kogi State of Nigeria revealed prescribing patterns  with a 
high tendency of poly-pharmacy. 
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2.3.2. Indiscriminate Use of Antibiotics    
Since the discovery of antibiotics, there has been tremendous reduction in infectious disease 
related mortality and morbidity diseases particularly in developing countries (Kakkilaya, 2006). 
Unfortunately, there are reports of widespread misuse and overuse of these life saving agents 
(Sivagnanam and Mohanasundaram, 2004; Kakkilaya, 2006; Dong, Yan and Wang, 2008). 
Currently, it is estimated that antibiotics account for 25-75% of all prescribed medications 
globally and they are the second most common category of medicines used in developing 
countries (Hogerzeil, Ross-Degnan and Laing, 1993; Akande and Ologe, 2007; WHO, 2010b). 
However, evidence has shown that significant proportions of antibiotics received by patients in 
developing countries are unnecessary (Holloway, 2004; WHO, 2009a).  
The WHO/INRUD initiated several intervention programmes with the aim of ensuring 
appropriate use of antibiotics and optimizing their usefulness in combating infectious diseases, 
particularly in developing countries where they are most needed considering the prevalence of 
communicable diseases in the countries (WHO/DAP, 1993; WHO, 2002; Holloway, 2004; 
WHO, 2004b; 2008; 2009c). Unfortunately, reports from these countries consistently reveal 
widespread misuse and overuse of antibiotics by prescribers (Holloway, 2002; Quick; 2003; 
WHO, 2004b). In a study conducted in 680 primary health clinics in Western China, antibiotics 
were prescribed in 48.43% of the prescriptions surveyed (Dong, Yan and Wang, 2008). 
Similarly, antibiotics were prescribed in 28.3% and 68.1% of the prescriptions surveyed in 
Western Nepal and South Africa respectively (Ghimire, et al. 2009; Mohlala,
 
et al., 2010).
 
 
The prevalence of inappropriate use of antibiotics has also been widely reported in studies 
conducted in Nigeria. For example Uzochukwu, Onwujekwe, and Akpala (2002) revealed that 
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72.8% of prescriptions surveyed in health centers implementing the BI contained antibiotics, 
while  Akande, Ologe and Medubi (2009) observed an overuse of antibiotics in University of 
Ilorin Teaching Hospital, Ilorin, Nigeria, where it was revealed that  83.5% of the prescriptions 
had at least one antibiotics prescribed. Several authors have noted the unnecessary and wasteful 
use of antibiotics in the treatment of common diseases like malaria, fever, sore throat and other 
cases where there are no clinical indications for their use (Nwoilsa, Erinuagha and Ofoleta 2006; 
Onwujekwe, et al., 2009; WHO, 2009a; Oshikoya and Senbanjo, 2010; Moorthi, et al., 2011).  
2.3.3   Overuse of Injections 
Clinically, injections are the most appropriate dosage form when immediate physiological action 
is required however; the use of injections is irrational when safer and more cost-effective routes 
of administration are available (2004a). To discourage unnecessary use of injections, a Safe 
Injection Global Network (SIGN) was established by the WHO in collaboration with countries 
and other international agencies with the aim of promoting and training health staff on rational 
and safer use of injections (Miller and Pisani, 1999). 
In spite of these measures, available information has shown that 15 billion injections are used 
annually in the world, the situation is worse in developing and transitional countries, which 
currently account for 70% of injection use in the world (Quick, et al., 2002; WHO, 2000a; 
Castrillo, Noel and Van Roekel, 2009; 2010b). In a comprehensive situation assessment of 
injection practices in primary health care hospitals in Bangladesh, Chowdhury, et al., (2011) 
found injections prescribed in 78% of the prescriptions surveyed. Overuse of injections in health 
facilities have been widely reported in studies conducted in Nigeria. According to Holloway 
(2004), about 38% of primary health care patients in Nigeria received injections and 
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Ugochukwu, Onwujekwe and Akpala (2002) found that a high proportion of patients (64.7%) 
were given injections in the BI health centres in South East of Nigeria.  
A consistent area of concern to the WHO is that the vast majority, estimated at about 90%, of the 
injections given in low income countries are unnecessary and unsafe (Quick, et al., 2002; WHO, 
2004b; Castrillo, Noel, and Van Roekel, 2009). For example in Nigeria, available evidence has 
shown that more than 70% of injections prescribed in Nigeria are not necessary (Quick, et al., 
2002; Holloway, 2004; Odunsaya, 2004).  
The wide spread use of injections in developing countries could be attributed to patients‟ 
preference for injections in the belief that injections are more effective than oral dosage forms, 
and the subsequent desire of physicians to satisfy patients‟ requests. Notwithstanding the reasons 
given for irrational use of injections, Quick, et al. (2002) argued that significant number of 
injections used in developing countries could have been given in oral dosage form. 
2.3.4.    Unnecessary Use of Branded Medicines 
Given the importance of medicines in health care, the policy priority of WHO is to ensure 
available and equitable access to affordable medicines (WHO, 2004b). To achieve this, the WHO 
advocated for the use of generic names as a policy for the procurement and prescribing of 
medicines in health facilities, bearing in mind that generics are usually cheaper than originator 
brand products (Laing, Hogerzeil, and Ross-Degnan, 2001). The generic names of medicines are 
the International Non-proprietary Names (INN) or official names of medicines.  Despite this fact, 
studies have shown that substantial proportion of the medicine budget in low and middle income 
countries is wasted on originator brand products in public health facilities (WHO, 2010b).  
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Assessments of prescriptions in developing countries revealed mixed findings on the compliance 
rates of countries with generic prescribing policies (WHO, 2004b). According to available 
evidence, while Mozambique and Zimbabwe have been able to attain a level of more than 90% 
of generic use of medicines in 1995 (WHO, 2004a), findings some developing countries showed 
much high proportions of originator brand names in the prescription encounters. In a prospective 
surveillance of drug prescribing and dispensing in the outpatient department a teaching hospital 
in Western Nepal, Ghimire, et al., (2009) observed only 13% of medicines were prescribed by 
generic name. Fattouh and Abu-Hamad, (2010) also found generic names used in only 5.5% of 
all the medicines prescribed in the prescriptions surveyed in government primary care clinics in 
the Gaza Strip.. 
Similar studies conducted in Nigeria demonstrated that the use brand names in prescribing was 
common in all public health facilities in the country. For example, assessments carried out by 
Akande and Ologe (2007) in public health facilities in Nigeria revealed that the percentage of 
medicines prescribed with generic names was as low as 41.9%. Similarly, Eze, and Olowu, 
(2011) found that use of generic names in 48.9 % of medicines prescribed in their study on 
prescribing patterns and use of medications in elderly outpatients in a tertiary hospital in Nigeria.  
While Enato and Chima (2011) observed that 37 % of medicines were prescribed using generic 
names. 
2.3.5   Poor Use of Essential Medicines List 
The WHO estimates that more than 50% of the population of developing countries lack regular 
access to medicines needed for the treatment of diseases (WHO, 2004a). To facilitate equitable 
and sustainable access to affordable medicines, the WHO in 1977 recommended the use of 
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medicines listed on an EML to guide in prescribing and facilitate access to medicines needed by 
the population (WHO, 2004a).  
Whilst it is currently estimated that over 70% of WHO member states now have national EML, 
the influence of EML on the prescribing practices of physicians remain poor in some countries 
(WHO, 2007a; Ahmed and Islam, 2012).  A systematic review of the patterns of use of 
medicines in primary health care settings in 104 low and middle income countries (LMIC) 
showed an increase in the percentage of medicines prescribed from  EMLfrom 70% in 1990 to 
87% in 2009 (Holloway, Ivanovska and Ross-Degnan, 2011). In an assessment of prescribing 
habits conducted in public and private health facilities in two provinces in South Africa, 
Mohlala, et al. (2010) showed that there was optimal use (92.6%) of medicines on the EML. A 
similar study in southwest Ethiopia revealed that the rates of medicines prescribed from the EML 
in the selected health facilities ranged from 89.09% to 91.85% (Angamo, Wabe and Raju, 2011).  
However, reports on use of medicines in some developing countries showed several cases of 
suboptimal use of the essential medicine list. For example, a study on antibiotic prescribing 
behavior of consultants in different localities of Pakistan, showed that only 30% of medicines 
prescribed were on the essential medicine list (Riaz, et al., 2010). In western Nepal, Ghimire, et 
al. (2009) found that the percentage of medicines prescribed from the EML in a teaching hospital 
in the country was poor at only (32.8%)..  
Findings from the WHO sponsored baseline assessment of the Nigerian Pharmaceutical sub-
sector showed that more than 90% of prescribed medicines were listed in the EML 
(FMOH/WHO, 2002). The study conducted by, Onwujekwe and Akpala (2002) equally reported 
high proportion (93%) of medicines prescribed from the EML in facilities operating the BI 
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medicine revolving scheme, however, the proportion was much lower (21%) in facilities outside 
the BI scheme. Another study conducted by Enato and Chima (2011) reported that only 82.3 % 
of medicines prescribed at the Federal Medical Center, Lokoja were from the EML. 
2.4   Consequences of Irrational Prescribing Practices 
Quality health services necessitate the maximization of the potential benefits of medicines while 
minimizing their hazardous effects. The problems associated with irrational prescribing of 
medicines have resulted in significant public health issues with regards to their implications on 
health outcomes, household and national expenditure on health and access to medicines. 
2.4.1. Health Implications 
The practice of poly-pharmacy has been found to be associated with risks of medication errors 
and unnecessary toxicity arising from medicine interactions, which may result in hospitalization 
and potentially life threatening effects (Neyaz, et al., 2011). The prevalence of hospitalization 
resulting from adverse drug reaction has been estimated to range from 5% to 16% in developed 
countries and 10 to 30% in developing countries (Hasford, et al., 2002; Iribhogbe and Agbaje, 
2011). Whilst the prevalence of death resulting from adverse drug reaction in developing 
countries is unavailable for comparison; the review of White, Araekelian and Rho (1999) on the 
implications of medicines use problems showed that adverse medicines reactions are the 4
th
-6
th
 
leading cause of death in USA.    
The public health threat associated with irrational use of injections is a major cause of concern 
amongst medical experts. The risks are obvious in patients‟ vulnerability to transmitting or 
contracting three preventable primary blood borne viral (BBV) diseases namely; Human 
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus; in addition to 
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the risk of tissue toxicity from local irritations and shocks associated with irrational use of 
injections (Holloway, 2004).  
According to WHO (2000a; b), several cases of paralytic polio in children were the 
consequences of unsafe use of injections by health care workers. This report is supported by 
evidence from the WHO's Global Burden of Disease study which revealed that annually, 32% 
cases of Hepatitis B Virus (HBV), 40% of new Hepatitis C Virus (HCV) infections and 5% of 
new HIV infections in developing and transition countries were associated with contaminated 
syringes and needles when administering injections (WHO, 2000a; b; Logez, et al., 2004). 
Another source of public health concern is the increasing emergence of bacterial resistance to 
first-line antibiotics that has been linked with continued misuse of antibiotics in health settings 
(WHO, 2005b; Shittu, et al., 2009; Onipede, Onayade and Elusiyan, 2009; Vila and Pal, 2010). 
This is particularly problematic in developing countries where there are reported cases of 
therapeutic failure resulting from 70-90% resistance rate to original first-line antibiotics, which 
are commonly used for the treatment of dysentery, pneumonia, gonorrhoea and hospital 
infections (Shittu, et al., 2009; Onipede, Onayade and Elusiyan, 2009; Vila and Pal, 2010). This 
invariably exacerbates the infectious disease related morbidity and mortality associated with 
developing countries, especially amongst the poor and vulnerable population who cannot afford 
the higher costs of second and third generation antibiotics (WHO, 2005b; Vila and Pal, 2010; 
Vila and Tibor, 2010).   
2.4.2. Cost Implications 
Evidence has shown that the misuse and overuse of injections and antibiotics exert unnecessary 
financial burden on household, hospital and government expenditure on medicines. Additional 
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costs are borne for administering injections to patients and switching to second or third line 
antibiotics in the event of resistance to first line antibiotics (Holloway, 2004). The author also 
noted that additional cost is also required for treatment of medicines-related morbidity. For 
example, Geer, et al., (2011), reported that USD 22469 was spent on hospitalization of patients 
presenting with adverse medicine reactions (AMRs) in Kashmir.  In Nigeria, Oshikoya, et al. 
(2007) found that USD 15, 466:60 was spent on the treatment of pediatric AMRs in a tertiary 
health facility in Lagos.  
Holloway‟s review estimated that irrational use of medicines and its attendant effects results in 
the wastage of between 50–70% of the government expenditure for medicines in developing 
countries (Holloway, 2004). A study on cost implication of irrational use of chloroquine in Lagos 
State government public hospitals in Nigeria revealed that 90% of the cost of procured 
chloroquine injection was lost to irrational prescribing (Aina.,Tayo and Taylor, 2008).  
According to experts on rational use of medicines, the cumulative cost of additional services and 
interventions from medicine toxicity may be unaffordable by the poor in developing and 
resource-constrained countries (Le Grand, Hogerzeil and Haaijer-Ruskamp, 1999; EDM, 2003; 
Holloway, 2005).  
2.4.3.   Effects on Availability and Universal Access to Health 
Rational use of medicines has been identified as one of the four medicines-specific factors that 
will ensure that medicines are accessible to people whenever and wherever they are needed. 
There is evidence to suggest that irrational prescribing practices and it attendant problem of 
medicine shortages partly accounts for the high proportion (estimated at over 50%) of 
populations of developing countries that lack access to essential medicines needed for quality 
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health services (MSH, 1997; Uzochukwu, Onwujekwe and Akpala, 2002; EDM, 2003; Aina, 
Tayo and Taylor, 2008).  
2.5     Initiatives for Promoting Rational Use of Medicines 
To ensure safe and cost-effective access to medicines and quality health service delivery, the 
WHO introduced a range of initiatives to facilitate optimal use and sustainable accessibility of 
quality medicines. These initiatives include the Essential Medicine Concept (EMC), the use of 
WHO/INRUD standard tools and indicators for measuring medicines utilization rate and Social 
Health Insurance Concept. 
2.5.1. Essential Medicines Concept                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The introduction of the Essential Medicine Concept (EMC) was informed by the need to guide 
member states in formulating policies that would assist health personnel, as well as consumers, 
in fulfilling the requirements of rational use of medicines, ensuring access to services and 
improving the health of the population (WHO, 2004b).  
Essential Medicines (EMs) are “those medicines that satisfy the health needs of the majority of 
the population which should be available at all times, in adequate amounts and in the appropriate 
dosage forms at a price the community can afford” (WHO, 1987). According to the concept, 
careful selection and use of a limited range of medicines will results in higher quality of care, 
more rational prescribing, cost-effectiveness and better management of available health 
resources (Laing, Hogerzeil and Ross-Degnan, 2001). The components of EMC include the 
following:  essential medicines list, standard treatment guidelines and use of generic medicines. 
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2.5.1.1 Essential Medicines List 
In 1977, the WHO drew up the first Essential Medicines Model List comprising of 208 
medicines selected on the basis of safety, approved efficacy and cost-effectiveness in treating the 
world‟s most common diseases to serve as a guide for member states in development of their 
Essential Medicine Lists or institutional formularies (HAI/WHO, 2000; Laing, Hogerzeil and 
Ross-Degnan, 2001). Additional criteria considered for the development of the country lists 
include the prevailing disease patterns of the country, changes in public health priority and levels 
of health facilities (WHO, 2002; Liu, 2003; Hogerzeil, 2004). The listed medicines form the 
EML of the country respectively. The WHO recommends regular updating of the list in view of 
innovative therapeutic options and the need for better medicines to cope with emerging new 
diseases, antimicrobial resistance and other health problems (HAI/WHO, 2000).  
The WHO and experts in rational medicines use programme maintain that the use of an EML as 
policy tool for procurement of medicines, health insurance reimbursement, and training and 
supervision of health workers will ensure rational use of medicines, sustainable affordability and 
availability of medicine as well as facilitate universal access to quality health care (Laing, 
Hogerzeil and Ross-Degnan, 2001, WHO, 2008). There is evidence to show that the introduction 
of the EML significantly improved prescribing practices in many countries, resulting in 
improved availability of essential medicines, decreased the production and utilization of 
medicines of doubtful effectiveness in many developing countries (Le Grand, Hogerzeil and 
Haaijer-Ruskamp, 1999; Liu, 2003; Hogerzeil, 2004; 2006) 
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2.5.1.2   Use of Standard Treatment Guidelines  
Standard Treatment Guidelines (STGs) are defined as systematically developed statements that 
are intended to enhance knowledge and aid physicians in making appropriate decisions for 
specific clinical circumstances; with the objectives of ensuring rational use of medicines, cost 
effectiveness, quality health care and improved health outcome (Liu, 2003). They are 
recommended for prescribers to guide in making appropriate diagnosis and specific prescribing 
practices (Liu, 2003). Evidence has shown that the use of STGs have helped to standardize 
treatment and proved to be effective in preventing wastage and improving  prescribing quality, 
availability of medicines and better health outcome in many settings (Hogerzeil, 1995; Le Grand,  
Hogerzeil and Haaijer-Ruskamp, 1999; Laing, Hogerzeil and Ross-Degnan, 2001; Quick, 2001).   
2.5.1.3   Generic Medicines 
The concept of rational use of medicines seeks to prevent unnecessary use of branded medicines 
where generic medicines of proven efficacy are available (WHO, 2004b). Generic names are the 
official International Non-Proprietary Names (INN) or shortened scientific names assigned to 
medicines globally. Generic medicines are bio-equivalent to their originator brand products in 
dosage form, safety, strength, route of administration, quality, performance characteristics, and 
intended use (Kings and Kanava, 2002).  
According to the concept, the use of generic medicines in procurement, prescribing and 
dispensing will ensure cost containment and regular availability in health facilities since they are 
cheaper, easier to identify and accessed globally than the branded  equivalents (Laing, Hogerzeil, 
and Ross-Degnan, 2001; Quick, 2001; Kings and Kanavo, 2002). In addition, available 
information has shown that generic medicines have enabled some countries to spend their limited 
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resources efficiently in procuring more medicines so that a wider coverage of patients would be 
achieved (Liu, 2003).  
2.5.1.4   Impacts of Essential Medicine Concept 
It has been found that appropriate application of all the components of the essential medicines 
concept in medicine utilization programmes has synergistic effects in achieving the collective 
goals of ensuring cost effectiveness of services, medicine availability and equity in access to 
quality health services (Hogerzeil, Walker and Sallami, 1989; Quick, 2001). Studies conducted 
in low and middle income countries including India, Iran and Yemen; estimated that the 
introduction of the national EML, generic prescription policy and treatment guidelines in health 
facilities led to great improvement in prescribing practices. It was estimated that savings from 
such improvement could constitute up to 30–70% of the national expenditure for medicines 
which could further be used to procure more medicines for more patients without affecting health 
outcome (Hogerzeil, Walker and Sallami, 1989; Chaudhury, et al., 1997; Le Grand, Hogerzeil, 
and Haaijer-Ruskamp, 1999; Quick, 2001; WHO, 2004).  
In Nigeria, there are mixed reports regarding the impacts of the components of essential 
medicines concept on prescribing practices across different public health settings. Some studies 
have shown that the implementation of the concepts in Nigeria has significantly improved the 
use of EML, prescription of generic based medicines and availability of essential medicines in 
health facilities (Uzochukwu, Onwujekwe and Akpala, 2002; Enato and Chima, 2011). However, 
evidence from other studies suggest that poly-pharmacy and unnecessary use of antibiotics 
remained a recurring medicine use problem in some public health facilities in Nigeria (Akande 
and Ologe, 2007; Akoria and Isah, 2009; Adebayo and Hussain, 2010).  
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2.5.2    Measuring Prescribing Practices 
Periodic monitoring and evaluation of medicines utilization practices are fundamental steps in 
identifying and quantifying potential medicines use problems and appropriate interventions in 
the health system (MSH, 1997; WHO/DAP, 93). According to Liu (2003), regular medicine 
utilization review could eliminate unnecessary and inappropriate use of medicine, which would 
result in reduced medicine-induced hospitalizations, unnecessary costs for medicines and 
improve quality of care. Hogerzeil (1995) asserted that assessment of medicine utilization cannot 
be effectively done without appropriate methodology and reference standards for measuring the 
degree of deviation from acceptable norms and for making comparisons between facilities, 
regions and countries.   
To assist member states in ensuring consistent, valid and standard identification and 
quantification of medicines use problem, the WHO Drug Action Programme on essential 
medicines (WHO/DAP) and International Network for Rational Use of Medicines (INRUD) 
developed sets of standard core and complementary indicators, which have been tested and 
recommended for medicines use studies in general out-patient departments (WHO/DAP, 1993; 
Hogerzeil, Ross-Degnan and Laing, 1993; Adebayo and Hussain, 2010). The core indicators 
consist of prescription indicators, dispensing and patient care indicators, and health facility 
indicators. The indicators have been used globally for assessing current medicines use practices, 
identifying potential medicines use problem and appropriate interventions where applicable. In 
addition, they are internationally endorsed for comparison of medicine use patterns across 
countries (WHO, 2002; 2004a; 2007b).  
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These tools have been successfully used in medicines utilization reviews programme globally 
(2002). Hogerzeil (1995) noted that medicine utilization review have resulted in substantial cost 
savings and improved the standards of health care services in  developed countries including the 
Netherlands, Mexico, the United Kingdom and the Medicaid  programme of the USA (Hogerzeil, 
1995). Several researchers have used these tools to successfully conduct studies on medicine 
utilization patterns in developing countries including Nepal (Ghimire, et al., 2009), Pakistan 
(Hafeez, et al., 2004), India (Karande, Sankhe and Kulkarni, 2005; Kumari, et al., 2008; Bhartiy, 
et al., 2008; Gaash, 2008), South Africa (Mohlala, et al., 2010), Ghana (Bosu and Ofori-Adjei, 
2000) and Nigeria (Uzochukwu, Onwujekwe and Akpala, 2002; Akande and Ologe, 2007; 
Adebayo and Hussain, 2010).  
To further encourage a standard approach in comparison of measuring medicine use problems in 
countries, it was recommended that the standard value for percentages of medicines prescribed 
by generic names and from essential medicine list should have a desirable optimal value of 
100%, which is regarded as the WHO standard values. However, the variations in countries‟ 
disease patterns necessitated the development of reference values for average number of 
medicines per encounter, percentage encounter prescribed injections and percentage encounter 
prescribed antibiotics based on countries specific morbidity patterns (Isah, et al., 2002; WHO, 
2004a).  
Several countries have generated local standards for these three indicators and the derived local 
standards have been used in combination with the WHO optimal values mentioned above (as 
WHO/Derived Reference Values) for measuring the degree of deviations in findings from studies 
on medicines utilization patterns in health facilities. Examples of such researches include studies 
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conducted in Malawi and Nigeria (Sosola, 2007; WHO/FMOH, 2002; Akoria and Isah, 2009; 
Enato and Chima, 2011; Eze and Olowu, 2011; Tamuno and Fadare, 2012).  
2.5.3    The Concept of Social Health Insurance  
In response to the recurring problems of poor funding and ineffective management of resources, 
the world health organization advocated for the institutionalization of Social Health Insurance 
Programmes (SHIPs) as alternative financing options for achieving universal access to health 
care stipulated in the MDGs (Brundtland, 2001; Hogerzeil; 2004; ICIUM, 2004; WHO, 2004b; 
2005a). The prepayment system of SHIPs “allows the healthy to subsidize the sick, and through 
income-based premiums, the rich to subsidize the poor. Both shifts imply that health care 
becomes more affordable for the poor and the sick” (Brundtland, 2003; WHO, 2004b:64). Funds 
pooled from various categories of contributors has the potential to increase the level of resources 
available for health care, ensure sustainable financing of medicines and guarantees equitable 
access to essential medicines at all times (Brunthland, 2000; Hogerzeil, 2004; WHO, 2004b).  
Evidence presented at the Second International Conference on Improving the Use of Medicines 
(at Chiang Mai, Thailand, 30 March – 2 April 2004), which was supported by the WHO, 
reaffirmed the effectiveness of health insurance in promoting appropriate use of medicines and 
improving access to cost-effective health care through effective use of the essential medicines 
concept (WHO, 2007a). Consequently, the Sixtieth World Health Assembly in resolution 
WHA60.16 urged member states to consider developing, strengthening and implementing, where 
appropriate, the application of an EML into the benefit package of existing or new insurance 
funds (WHO, 2007a). This, according to the WHO, would accelerate their progress towards the 
attainment of universal access to medicines and health care (WHO, 2005a).         
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The recommendation was based on the concept that health insurance is associated with various 
administrative and managerial approaches to programmes that control cost, influence rational use 
of medicines and ensure availability of medicines (WHO, 2004b). Such strategies include 
collation of data on their enrollees, health service providers, services utilized and expenses 
incurred. These enable the monitoring and tracking of information on medicines utilization and 
cost of services with the objectives of designing policies and strategies that will ensure 
appropriate use of medicines (Carapinha, et al., 2010; Faden, et al., 2011).  
Insurance programmes also define medicines benefits and coverage limit, terms of re-
imbursement to consumer and health care providers. In some countries, including Nigeria, the 
system implements Separation of Prescribing and Dispensing policy (SPD), which aims at 
reducing potential conflict of interest and expenditures on medicines, and promoting appropriate 
use (Faden, et al., 2011). Other strategies include; claims verification, cost sharing system such 
as co-payment and capitation system of paying providers. In addition, the system uses STG, 
generic medicines based formularies, and generic reference pricing which is used as the basis for 
calculating copayment and re-imbursement of fee for services (Hogerzeil, and Ross-Degnan, 
2001; Carapinha, et al., 2010; Faden, et al., 2011).  
There is a substantial evidence that suggests that these strategies had led to more rational use of 
medicines, expanded medicine benefits and cost containment of expenditure of medicines in 
health insurance programmes of some developing countries including Iran, Thailand, Taiwan and 
Philippines (Yesalis, Norwood and Lipson, 1994; Dong, et al., 1999; EDM, 2003; WHO, 2004b; 
Hogerzeil, 2004; Chu, Liu and Romeis, 2008; Faden, et al., 2011). 
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2.6 Prescribing In Health Insurance Settings 
Reports from previous studies have demonstrated large variations in prescription patterns in 
health insurance settings. There is ample evidence that suggest that social health insurance 
schemes were associated with the observed increase in the number of essential medicines 
prescribed, increase in the number of medicines prescribed with their generic names; and a 
reduction in antibiotics and injections prescribed in some parts of China and Lao People's 
Democratic Republic (Dong, et al., 1999; Syhakhang et al, 2011). However, a few studies in 
some developing countries contradict the positive findings on the effects of health insurance on 
prescribing practices. For instance, a study conducted in Shandong Provinces of China to assess 
the prescribing patterns in health insurance operating facilities confirmed this theory. The results 
revealed that over use of antibiotics, injections, and poly-pharmacy were common in townships 
and village hospitals with and without health insurance programme  (Sun, et al., 2009).  
The report of a study on Philhealth insurance programme in Philippines also showed that the 
scheme was marred with overcharging, excessive admission, irrational prescribing practices and 
high co-payment (WHO, 2004b).  
A similar study conducted in Iran to ascertain the impact of interactive programme on rational 
prescribing by physicians in social health insurance settings showed high use of antibiotics, 
corticosteroids and injections by physicians (WHO, 2003b; 2009d; Hosseini, Banihashemi and 
Darbooy, 2011). This is not surprising given the fact that many insurance schemes in developing 
countries lack appropriate framework for monitoring the activities of providers who can easily 
engage in irrational prescribing (Brundtland, 2001).  A report by Bjerrum (1998) found that poly-
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pharmacy was frequent in county health insurance services of Funen in Denmark; confirming the 
existence of irrational prescribing in health insurance programmes in some developed countries.  
2.6.1   Framework for Appropriate Prescribing in Social Health Insurance Programmes in 
Nigeria. 
To effectively prevent irrational use of services in the scheme introduced in Nigeria, the NHIS-
council developed a set of tools and regulations including Operational Guidelines, Essential 
medicines and price list and NHIS Standard Treatment and Referral Protocol (STG) which are 
provided to accredited providers. These tools were intended to assist stakeholders in delivering 
cost effective services (FMOH, 2005a; b; c). The operational guidelines strongly emphasize on 
strict adherence to the concepts of rational use of medicines, and compliance with specifications 
in the guidelines is mandatory to qualify for re-imbursement of fees for services rendered.  
2.6.2    Studies in Social Health Insurance Setting in Nigeria 
There is a dearth of studies on prescribing practices in the Social Health Insurance Programmes 
in Nigeria, though there have been reports of shortages of medicines, non reimbursement for 
medicines paid by insured patients and non referral of prescriptions to accredited private 
pharmacies (Uwagu, 2009, Sanusi and Awe, 2009). The few studies conducted in health 
insurance accredited health facilities reported poor availability of medicines and various forms of 
irrational prescribing. For instance, a qualitative research carried out in Oyo State in Nigeria 
revealed that 72% of the respondents wanted discontinuation of the programme attributing their 
action to poor services from providers, shortages of medicines and unofficial payments for 
services covered in the benefits package (Sanusi and Awe, 2009). Another study conducted by 
Adebayo and Hussain, (2010) on the patterns of prescription at the Nigeria army hospitals at 
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Kano, Yaba and Lagos, found an average of 2.8 ± 1.5 medicines per prescription encounter, 
49.3% of medicines prescribed with their generic names and 28.1% of prescription encounters 
containing at least one antibiotic.  
However, there are several limitations in these studies which necessitate further research. For 
example, the qualitative research conducted by Sanusi and Awe (2009) failed to assess the 
prescribing and dispensing practices as possible causes of shortages of medicines and poor 
services. The results of the studies conducted by Adebayo and Hussain (2010) were not analysed 
in relation to the WHO/Derived Reference Values for Nigeria (Isah, et al., 2002). In addition, the 
results cannot be generalized to health insurance programme because the sampling methodology 
did not exclude prescription sheets of uninsured patients.  
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CHAPTER THREE 
METHODOLOGY 
 
3.0   Introduction 
Chapter three introduces the aims and objectives of this study. It describes the study population 
and justifies the choice of study design, sampling methods, data collection techniques as well as 
determination of sample size. The methodological processes including the measures undertaken 
to fulfill the requisite ethical issues, recruitment of data collectors, pre-testing of tools and the 
documentation of data on the data collection forms are extensively discussed in this chapter. The 
chapter then describes the procedure employed for management and analysis of data, the 
methods of results presentations; and concludes by describing the measures undertaken to ensure 
validity and reliability of data. 
3.1 Aim of the study 
To investigate prescribing practices in the Social Health Insurance Programme in accredited 
public sector secondary hospitals in the Federal Capital Territory, Nigeria.  
3.2 Objectives 
1. To describe prescribing practices in the Social Health Insurance Programme in accredited public 
sector secondary hospitals in the Federal Capital Territory, Nigeria. 
2. To identify and quantify irrational prescribing of medicines in the Social Health Insurance 
Programme in Federal Capital Territory, Nigeria. 
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3. To measure the percentage of prescribed essential medicines that was dispensed to beneficiaries 
of the Social Health Insurance Programmes in Federal Capital Territory, Nigeria. 
3.3 Study Design 
This study used a cross-sectional, descriptive methodology to survey retrospective records of 
prescription sheets of Social Health Insurance enrolees in accredited public sector secondary 
hospitals in the Federal Capital Territory, Nigeria. The choice of cross-sectional design was 
based on its ability to identify and quantify the variables contributing to medicine use problems 
(Grimes and Schulz, 2002; Beaglehole, Bonita and Kjellstrom, 2006). Second, it meets the 
WHO‟s recommendation that cross-sectional study designs can be used to study the trend in the 
use of medicines for one year to ensure equal representative  samples and arrive at valid results 
devoid of biases (WHO,1993). The feasibility of generalizing the findings from cross-sectional 
studies to the study population is high (WHO/DAP, 1993; Durrheim and Painter, 2006; Park, 
2007). Third, a review of literature on the use of medicine practices suggests that most baseline 
studies or studies on the prevalence of irrational use of medicines in Nigeria and other parts of 
the world used cross-sectional study designs (Uzochukwu, Onwujekwe and Akpala, 2002; 
Holloway, 2002; Araoye, 2003; Akande and Ologe, 2007; Adebayo and Hussain, 2010). 
A retrospective data collection technique was employed to review the prescription encounters. 
This permitted examination of past trends in the use of medicines within a year and helped 
minimise bias due to seasonality and variations in the medicine supply cycle. The review of 
literature on prescribing practices revealed that a substantial number of studies conducted in 
Nigeria relied on retrospective review of patient records for collection of a large amount of data 
(Uzochukwu, Onwujekwe and Akpala, 2002; Akande and Ologe, 2007; Adebayo and Hussain, 
2010).  
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3.4   Study Population  
The study population consisted of the following: 
a). All the 13 functioning public sector secondary hospitals managed by the Health and Human 
Services Secretariat (HHSS), Federal Capital Territory, Abuja. They constituted the primary unit 
of study. The initial plan was to use all the 14 public sector hospitals in FCT as the study 
population, however, according to information from the FCT Health Research Committee, only 
13 of the 14 hospitals were operational. The newly constructed hospital at Karu has not 
commenced operational activities at the time of the survey.  
b) The prescription encounter records of the NHIS out-patients representing a mix of health 
problems and ages constituted the secondary unit of study.  
3.5 Sampling Procedure             
3.5.1 Determination of Sample Size 
a) Four public sector hospitals were selected as the primary unit for this study.  
b) A total of Seven hundred and twenty (720) copies of prescription encounters were selected 
retrospectively from the selected secondary hospitals as the secondary unit of study. This sample 
size was well above the WHO specification for a cross-sectional survey of prescribing practices, 
which stipulates a minimum of 600 prescription records for 20 hospitals, or 100 records for a 
single health facility. The decision to use a large sample size was to ensure effective 
representative of all the variations in the study population (at a confidence interval of plus or 
minus 5% error and at 95% confidence level) as well as to further enhance the validity of data 
(Hedges, 1978; WHO /DAP, 1993; Durrheim and Painter, 2006). 
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3.5.2 Sampling of Hospitals 
To generate representative samples, a Multistage sampling technique was used for the selection 
of the hospitals: 
First, 13 secondary care hospitals were stratified into urban/peri-urban areas. 
a) Six urban hospitals which have high concentration of patients in attendance with 80-150 patients 
per day and 10-20 insured patients in attendance per day. These include: Wuse, Garki, Asokoro, 
Kubwa, Maitama and Gwarinpa hospitals.  
b) Seven peri-urban- hospitals which have low concentration of patients in attendance with at least 
20-40 patients per day and 5-10 insured out-patients in their daily attendance register, they 
consist of  Abaji, Bwari, Nyanya, Karshi, Kuje, Kwali and Rubochi hospitals. Each peri-urban 
area is not more than one hour drive from the urban area. 
 
Second, two hospitals were randomly chosen from each of the strata. This was done by writing 
the names of the hospitals in each group on small pieces of folded paper in two separate bowls; 
thereafter, one of the data collectors randomly picked two of the folded pieces of papers from 
each of the two bowls. Hospitals were coded according to the stratum from which they were 
selected. The two hospitals generated from the peri-urban stratum were coded PAH and PBH; 
while hospitals selected from the urban stratum were coded UAH and UBH. 
3.5.3    Sampling of Prescription Encounters 
The prescription encounters of the Social Health Insurance out-patients from July 2009 to June 
2010 constituted the sampling frame. Copies of the prescription sheets from each hospital were 
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gathered and sorted in monthly order. Indelible and torn prescriptions sheets were excluded from 
the sampling process; the remaining were counted and recorded for each month.  
Fifteen prescriptions were systematically selected from each of the 12 months. The sampling 
interval was determined by dividing the total number of prescription encounters recorded for a 
given month by the number of cases needed per month. The random number used as the starting 
point for each selection was determined by throwing a dice. The derived number was used 
repeatedly to systematically select 15 prescription sheets for each month of encounter for a year 
(June 2009 to July, 2010) until 180 prescription encounters were selected per hospital, and 720 
prescriptions for the four hospitals. This method has been employed in previous studies in 
Nigeria (Castrillo, Noel, and Van Roekel, 2009). 
3.6   Data Collection  
3.6.1 Data collection instruments 
The WHO/DAP INRUD standardized methodology, tools and indicators recommended in the 
WHO guidelines on “How to investigate medicine use in health facilities” (WHO/DAP, 1993), 
were adapted and used in this study.  
The modified tools consisted of three forms:  
Data Compilation Form 1: This form was modified to capture data on patients‟ identifier codes, 
names of medicines prescribed, route of administration and formulation type, the number of 
medicines actually dispensed per prescription encounter and number of prescriptions referred to 
other accredited pharmacies (Appendix 4).The design of the form also helped in quality 
checking, tracking and tracing missing data. 
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Prescribing and Dispensing Indicators Form 2: This form was restructured to record the detailed 
information on patterns of prescribing and dispensing of medicines. The recorded data included 
the number of medicines prescribed per encounter, encounters with injection or antibiotics 
prescribed number of medicines prescribed from the NHIS Essential Medicines Formulary, 
number of generic medicines prescribed per encounter, number of medicines dispensed in 
hospitals under study and the number of medicines dispensed through referral of prescriptions to 
accredited pharmacies outside the hospitals (Appendix 5). 
Facility Summary Form 3: This form was also modified to describe all analytical results on the 
prescribing indicators including average number of medicines per encounter, percentage of 
medicines prescribed by generic name, percentage of encounter with antibiotic prescribed, 
percentage of encounters with injection prescribed, percentage of medicines prescribed from the 
NHIS Essential Medicine Formulary, percentage of prescribed medicines dispensed at the 
selected hospital and percentage of prescriptions referred (Appendix 6).  
3.6.2. Preparations for Data Collection 
Prior to the commencement of data collection, extensive preparatory activities were carried out 
to facilitate smooth data collection processes. The activities include the following: 
3.6.2.1   Visits to stakeholders 
Key health insurance stakeholders including the NHIS corporate office, FCT Health and Human 
Service Secretariat and some HMOs were visited to inform them of the study and to seek their 
support and participation. A copy of the proposal was submitted to each of them, this resulted in 
the release of letters of approval for the research from the Health and Human Service Secretariat, 
FCT, Abuja; and support from the NHIS corporate head quarters.  
 
 
 
 
 43 | P a g e  
 
The letter of approval for the research was presented to each of the Chief Pharmacists in the 
selected hospitals; this was aimed at ensuring adequate notification of the purpose and methods 
of the study and to seek their support. The Chief Pharmacist and staff of the pharmacy units in 
each of the selected facility responded positively as was evidenced in the assistance given in 
identifying and arranging the required prescription copies and interpreting information on 
prescription sheets or dispensing logbooks when necessary. The visitation to the hospitals also 
provided opportunity to introduce the data collectors, confirm availability of required records 
and estimate the time required to conveniently collect data from each of the facility without 
disturbing the routine works of the pharmacy units. 
3.6.2.2 Selection and Training of Data Collectors 
A team of data collectors comprising health professionals including the principal investigator, 
two pharmacists, a microbiologist and two pharmacy technicians were engaged and trained on 
the data collection process. Each of the data collectors has a minimum of five years work 
experience in reading and dispensing prescriptions in various hospitals and pharmaceutical 
outlets. Their knowledge of pharmaceutical terms enhanced accurate extraction of information 
from prescription records and interpretation of prescriptions.  
All data collectors were trained together in three training sessions. The training covered the 
following topics: how to effectively use the research tools, the types of data to be extracted from 
prescriptions sheets, how to identify prescribed medicines, route of administration, medicines 
dispensed and referred, and how to record them on the  appropriate column of the data collection 
tools. Other components of the training included sampling procedures, ethical issues and 
confidentiality in handling administrative and clinical documents and research findings.  
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At the end of the training, data collectors were divided into two teams. A team was assigned to 
the urban hospitals while the other covered the peri-urban hospitals. A survey schedule was 
arranged for each facility to ensure that the chief investigator fully participated in collection of 
data from each study facility to enable effective supervision.  
3.6.2.3 Data Collection Guidelines 
To avoid ambiguity in collection of data, each data collector was given a copy of the NHIS-EML 
formulary as the reference list for identifying what constitute generic medicines and antibiotics, 
and measuring the number of medicines prescribed from NHIS-EML list. In addition, a protocol 
was designed to assist in interpreting unclear prescription and identifying the data to be collected 
(Appendix 7). A list of abbreviated names of medicines commonly used by prescribers in 
Nigeria was given to the data collectors for easy identification of such medicines (Appendix 8)  
It was also decided that collection of data should take place between 11a.m. and 1:30 p.m. from 
Tuesday to Thursday every week. The choice of this period was based on the fact that Mondays 
were very busy days, and the hours between 9 a.m  and 11 a.m was the peak of activities in the 
NHIS dedicated pharmacy units; which usually open for activities from 8:30 a.m and closes 2:00 
p.m. 
3.6.2.4 Pre-Testing of Instruments and Procedures  
The tools used in this study were pre-tested in one of the hospitals not selected for the study. The 
field test offered an opportunity to identify problems associated with the sampling procedures 
and completion of the instruments. To ensure reliability of data and content validity, the 
feedback from the pre-testing was used to further modify the study instruments. The Prescribing 
and Dispensing Indicators Form 2 was modified to capture additional data on prescribed 
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essential medicines dispensed, while the Facility Summary Form 3 was re-designed to capture 
data on the proportion of prescribed essential medicines dispensed and the proportion of 
prescription encounters having all prescribed medicines completely dispensed to insured 
patients.  
3.6.3 Data Collection Procedures 
The retrospective data on prescription encounters were collected within two months, from March 
7
th
 to May 5
th
 2011, with the aid of the three WHO adapted data collection instruments described 
above. All information on medicines prescribed and referred were abstracted from the sampled 
prescription encounters and documented on the corresponding portion on the Data Compilation 
Form 1. In this study, referral was defined as prescriptions containing prescribed medicines not 
completely dispensed in the study facilities. These were assessed to determine if the prescribed 
essential medicines were dispensed in other accredited providers as stipulated by the guidelines. 
Detailed information describing the prescribing patterns and the extent to which the hospitals 
ensure that prescribed medicines were available to patients was extracted and entered into the 
designated section of Prescribing and Dispensing Indicators Form 2 for each facility.  
Availability of medicines was assessed by: 
First, measuring the number of medicines dispensed in the study facilities by tracing the name of 
patients, date of prescription and names of medicines prescribed on each sampled prescription to 
the corresponding details on the dispensing logbooks to determine the number of medicines 
dispensed.  
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Second, determining the number of medicines dispensed through the process of referral to other 
accredited providers. This was done by identifying prescriptions with prescribed essential 
medicines not completely dispensed thereafter, we requested to review pharmacy records to 
determine the number referred to other providers and the number of re-imbursement made in 
respect of the referred prescriptions. 
To facilitate statistical analysis, the documentation of information such as prescriptions with 
antibiotic or injection prescribed and prescription referred were assigned with the codes  “0”  or 
“1” on the respective column in the Prescribing and Dispensing Form 2.  The code “0” infers 
that no antibiotic or injection was prescribed, and no prescription was referred to any accredited 
pharmacy; on the other hand, the code “1” indicates that an antibiotic or injection was 
prescribed. In terms of dispensing of prescription, “1” also infers that a patient was referred to 
another facility to get his/her remaining prescribed medicines dispensed. The numerical variables 
including number of medicines prescribed or dispensed, number of medicines prescribed from 
the EML, and number of prescriptions referred were not assigned with codes. 
The summary results of all the findings in the study per facility were transferred to the relevant 
sections on the Facility Summary Form 3.  
3. 7   Data Management 
At the end of the data collection, completed forms were brought to a central place for further 
review and data cleaning. All detected inaccurate entries or missing data were corrected using 
the prescription identifier code to trace the corresponding sampled prescription encounter 
(Joubert and Erhlich, 2007). Data were entered into Microsoft Excel
TM
 spreadsheets over one 
week by two dedicated typists and cleaned to ensure that unknown values did not appear in the 
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data set. Thereafter, data were imported into Epi-info version 3.4.3 for further cleaning and 
quality checks to ensure completeness and consistency.  
3.8 Data Analysis 
Epi-info version 3.4.3 and SPSS (Statistical Program for Social Science, version 17.0) were 
employed to generate means (average), percentages, range, confidence intervals and p-values.  
One-way ANOVA was used to determine the statistical difference among the means of the four 
hospitals, followed by Chi-Square tests to determine the statistical significance of the differences 
in the percentages of the prescribing indicators. P-values < 5% were considered as statistically 
significant.  
Summary statistics of means and percentages of medicines prescribed were used to describe and 
quantify the prescribing practices in relation to the degree of poly-pharmacy, the tendency to 
prescribe by generic names, the overall level of use of antibiotics and injections; and the degree 
to which prescriptions conformed to the Essential Medicine List as indicated by the NHIS- 
medicine formulary. The statistical measures were also applied to determine the extent to which 
hospitals were able to provide the medicines which were prescribed, and the proportion of 
patients who have all their medicines completely dispensed.  
Findings were presented in the form of tables and bar charts to display the different levels of 
each indicator for each facility, and comparisons were made with findings from previous studies 
in Nigeria and other developing countries. The rationality of prescribing and availability of 
medicines were determined by comparing the results with the WHO/Derived Reference Values 
which consist of the WHO standards values and local standards derived for two states in Nigeria 
(Table 4.1).  
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3.9 Validity 
Validity is the ability of a study to measure what it intends to measure to give a sensible result 
(Beaglehole, Bonita and Kjellstrom, 2006).  A range of checks were undertaken in this study to 
ensure validity of data. 
To ensure content validity, pharmaceutical reference books including EMDEX (The complete 
Drug Formulary for Nigeria‟s Health Professionals) and Martindale Extra Pharmacopeia were 
used as guides to determine the generic equivalent of all prescribed branded medicines in order 
to ascertain their availability in the EML. The appropriateness in the use of prescribed medicine 
was determined by using the NHIS-Essential Medicine Formulary. 
The coding of each prescription encounter was structured in such a way that information bias due 
to missing data, or wrong data documentation was minimised by ensuring ambiguous data were 
further clarified by tracking the number of data on the form to the corresponding prescription 
sheets with the use of assigned codes and subsequently correcting the entries until clarity of the 
data was captured. 
Confounding occurs when a third variable is strongly associated with the study variables in the 
study population thereby making it difficult to determine the factors truly responsible for the 
results obtained in a study (Joubert and Erhlich, 2007). In this study, potential confounding bias 
were minimized by using the NHIS Essential Medicines Formulary as terms of reference, 
therefore all medicines in semblance with antibiotics such as anti-protozoas and anthelmintics, 
which were not considered as antibiotics in the NHIS formulary were not regarded as such; 
however, all combination medicines and topical agents containing antibiotics were regarded and 
counted as antibiotics.  
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Selection bias was minimized by ensuring that only prescription encounter records of social 
health insurance patients from the general outpatient department were included in this study.  
The adoption of retrospective data collection techniques also reduced conceptual biases that 
could have risen from seasonal variation, interruption of medicine supply, and the susceptibility 
of information biases arising from change in prescribers‟ attitude in the presence of researchers 
(WHO/DAP, 1993). 
3.10 Reliability 
Reliability demonstrates the extent to which the instruments or tools yield the same results on 
repeated trials under the same setting (Beaglehole, Bonita and Kjellstrom, 2006). Studies have 
shown that random sampling and measurement error are major factors that influence the 
reliability of any given research (Myer and Karim, 2007; Joubert and Erhlich, 2007).  
In this study, the use of large sample size of 720 prescription encounter records and multi-stage 
sampling technique helped to ensure equal representation of the various variables in the study 
population and minimized errors from random sampling error (Grimes and Schulz, 2002; 
Beaglehole, Bonita and Kjellstrom, 2006). Measurement errors were minimized with the use of 
the WHO standardized measuring tools and indicators; which were adapted and pre-tested before 
the commencement of data collection in health facilities.  
3.11   Generalizability of Results  
The results of this study are only applicable to the study population, however, the 
generalizability of the findings to the NHIS formal sector health insurance programne in other 
public sector secondary hospitals was enhanced by the choice of study facilities which are 
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affiliated to more than 50% accredited HMOs for formal sector scheme and the use of a large 
sample size which ensured good representation of insured patients.    
3.12    Ethical Consideration. 
Ethical clearance and approval for this study was first given by the Health Research and Ethics 
Committees of the University of the Western Cape and the NHIS corporate headquarters. 
Thereafter, ethical permission to conduct the research in the selected hospitals was granted by 
the Health Research Ethics Committee in FCT through the Chairman; the Secretary of Health 
and Human Services - under whose authority these hospitals function (Appendix 9). In addition, 
the NHIS corporate headquarter was also informed and their consent was solicited before the 
commencement of the study. 
Confidentiality of the names of the selected hospitals and the insured patients was maintained by 
assigning codes to each of the selected hospitals and prescription encounter sheets. The data 
collection forms also reflect the codes of the selected hospitals and prescription encounter sheets 
so that information from the sampled prescription encounter sheet was documented against the 
corresponding codes on the data collection forms. The privacy of data was further assured by 
ensuring that data was stored in the computer with a password known only to the researcher and 
hard copies of data collected were stored in a safe at all times and will be destroyed after a period 
of five years.    
Copies of this study will be submitted to the University of the Western Cape in partial fulfillment 
of the requirements for the Masters in Public Health degree. Also, soft copies would be 
disseminated to the NHIS corporate headquarters, heads of all the 13 secondary hospitals through 
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the Secretary of Health and Human Services; and all the HMOs affiliated to the study facilities 
(Appendix 10).  
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CHAPTER FOUR 
RESULTS 
 
4.0 Introduction 
In this chapter, the findings of this study on prescribing practices and availability of essential 
medicines are presented. The study was conducted in four selected public sector hospitals in the 
Federal Capital Territory, Nigeria, two peri-urban and two urban hospitals identified as PAH, 
PBH and UAH, UBH respectively. The study sampled 180 prescription encounters from each of 
the four hospitals selected for the study. Overall, 720 prescription encounters were examined and 
the information analyzed with the use of the WHO prescribing and dispensing indicators. The 
results are presented as averages, percentages and frequency of distribution of variables as tables 
and charts. The rationality of prescribing was determined by comparing results with the 
WHO/Derived Reference Values as detailed in Table 4.1 (WHO, 2004, Isah, et al., 2002). The 
first section of this chapter describes the WHO/Derived Reference Values, followed by a 
description of prescription patterns across the four hospitals and concludes by describing the 
extent of availability of prescribed medicines to patients. 
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4.1 Description of WHO/Derived Reference Values 
 
Table 4.1: WHO/Derived Reference Values for Prescribing and Patient Care (Medicines 
dispensed) Indicators 
 
  
 
 
 
 
(WHO, 2004a: Isah, Quick, Mabadeje, Santoso and Hogerzeil, 2002) 
Table 4.1 shows the WHO/Derived Reference Values which are a combination of the WHO 
standard values and local standards derived from two states in Nigeria; they were used in 
determining the appropriateness of prescribing patterns and the degree of availability of 
medicines in this study.  
The WHO global standard values for percentages of generic medicines prescribed from the EML 
and medicines dispensed are an optimal value of 100% each. However, based on morbidity 
patterns and the results of a study conducted in two states in southern Nigeria, the values derived 
for the average number of medicines prescribed, percentage of prescriptions with antibiotics and 
injections prescribed are within the ranges of 1.6-1.8, 20.0- 25.4% and 10.1-17.0% respectively.  
Indicators Values Type 
Average No. of Medicines prescribed 1.6 - 1.8 Derived standard    
% of Prescription encounters with an 
antibiotic prescribed. 
20.0 – 25.4 %   Derived standard   
% of Prescription encounters with an 
injection prescribed 
10.1 – 17.0%   Derived standard   
% of Medicines prescribed by generic name. 100% WHO standard 
% of Medicines prescribed on   EML  100% WHO standard 
% of Medicines actually dispensed 100% WHO standard 
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The wide range assigned to the indices of antibiotics and injections is due to the prevalence and 
severity of communicable diseases and other local factors which may influence the indices in 
varying degrees. 
4.2 Description of the Patterns of Prescribing 
The following section provides an overview of prescribing patterns in the social health insurance 
programme in accredited public sector hospitals in FCT, Abuja. The section identified the nature 
and magnitude of irrationalities in the prescription encounters of insured patients. 
Table 4.2: Frequency of medicines prescribed per encounter (n=2517) 
No. of 
Medicines Per 
Prescription 
Encounter 
PAH PBH UAH UBH OVERALL 
Freq % Freq % Freq % Freq % Freq % 
1 2 1.1 2 1.1 4 2.2 0 0 8 1.1 
2 22 12.2 46 26 39 21.7 21 11.7 128 17.8 
3 48 26.7 72 40 56 31.1 54 30 230 31.9 
4 75 41.7 47 26 51 28.3 59 32.8 232 32.2 
5 30 16.7 10 5.6 22 12.2 35 19.4 97 13.5 
6 3 1.7 3 1.7 8 4.4 11 6.1 25 3.5 
Total 180 100 180 100 180 100 180 100 720 100 
 
One of the most commonly used indicators for determining rational prescribing is the number of 
medicines prescribed per encounter. The frequency of the number of medicines prescribed per 
encounter in the study population is presented in Table 4.2; and it ranged from one to a 
maximum of six medicines per encounter. In PAH, PBH and UAH hospitals, the prescription 
encounters resulted in one or more prescribed medicines; however, in UBH the number of 
prescribed medicines per encounter ranged from 2 to 6. Overall most encounters resulted in three 
 
 
 
 
 55 | P a g e  
 
or four prescribed medicines, with almost one third of encounters resulting in three prescribed 
medicines and another third in four prescribed medicines.  
The study also revealed that 81.1% of the study population had three or more medicines 
prescribed. Further analysis showed that PBH exhibited the highest poly-pharmacy with 88.3% 
of its entire prescription encounters having three or more medicines prescribed; this was 
followed by PAH (86.8%), UAH (76.0%) and PBH (73.4%).  
Table 4.3: Mean number of medicines prescribed per prescription encounter (n = 2517) 
Hospital  Number  of 
Prescription 
Encounters 
Number of 
Medicines 
Prescribed 
Mean Number 
of Medicines 
Prescribed 
Minimum Maximum 
PAH 180 658 3.7 ± 1 1 6 
PBH 180 566 3.1 ± 1 1 6 
UAH 180 612 3.4 ± 1 1 6 
UBH 180 681 3.8  ± 1 2 6 
OVERALL 720 2517 3.5 ±1 1 6 
Analysis of Variance (F) = 13.2,    p< 0.001 
Table 4.3 shows that the average number of medicines prescribed per encounter in the study 
population was 3.5±1 compared to the WHO/Derived Reference Values which ranged from 1.6 - 
1.8. The average number of medicines prescribed per encounter varied between the hospitals 
from a minimum average of 3.1 found in PBH to a maximum average of 3.8 found in UBH. A 
significant difference (p< 0.001) was found and the results show that PBH, with a mean of 3.1 
had the least tendency towards poly-pharmacy compared to the other hospitals.  
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Table 4.4: Most commonly prescribed medicine categories (n=2517) 
Categories of Medicines 
Prescribed 
OVERALL PAH PBH UAH UBH 
  % Rank % Rank % Rank % Rank % Rank 
Analgesics/NSAID                                                          19.2 1 19.1 2 21.2 2 18.3 1 18.4 1 
Antibiotics 17.6 2 18.5 3 22.8 1 15.7 3 14.2 4 
Antimalarials 17.3 3 19.6 1 17.8 3 13.2 4 18.2 2 
Haematinics/Vitamins 13.3 4 9.4 4 12.2 4 16.2 2 15.3 3 
Antihypertensives 6.6 5 3 9 2.8 7 10.1 5 9.5 5 
Antihistamines 4.3 6 5.6 5 5.5 6 3.6 7 2.5 9 
Anti-flagellates  3.6 7 3.5 8 2.3 9 4.1 6 2.9 8 
Anti-ulcers 3.5 8 4 6 2.7 8 2.6 9 4.6 6 
Sedatives/ Tranquilizers 2.1 9 2.4 11 9 5 2.1 10 2.1 10 
Anthelmintics  1.8 10 3 9 1.7 11 2 11 1.8 11 
Antidiabetics 1.7 11 0.8 12 0.4 13 2.3 8 3.4 7 
Antifungals 1.6 12 1.7 7 1.5 12 1.6 12 1.4 12 
Corticosteroids 1.2 13 0.8 13 1.8 10 1.3 13 1.2 13 
 
The most commonly prescribed medicine categories are ranked according to their frequency in 
Table 4.4. Analgesics/NSAIDs were the most prevalent medicine category accounting for 19.2% 
of the total medicines prescribed in the four hospitals. The four most frequently prescribed 
categories of medicines were analgesics/NSAID, antibiotics, antimalarials and 
haematinics/vitamins, they constituted 19.2%, 17.6%, 17.3% and 13.3% of the 2517 medicines 
prescribed across the four hospitals respectively; and collectively accounted for 67.4% of the 
overall medicines prescribed. These four categories of medicines comprised the top four 
categories across all four hospitals. The findings with regard to the use of anti-infective and anti-
parasitic agents revealed that antimalarials, antibiotics and antiflagellates were on the top-ten list 
of commonly prescribed medicines  in all four hospitals, however, anti-fungal agents were also 
amongst the top ten medicines categories in PAH, and anthelmintics were on the top ten list in 
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PAH and UBH facilities. Overall, antibiotics (17.6%), antimalarials (17.3%), anti-flagellates 
(3.6%) and anthelmintics (1.8%) accounted for 40.3% of the total (2517) medicines prescribed in 
the study population.  
 
Chi- X
2
= 2.8, p= 0.4      
Figure 4.1: Percentage of prescription encounters with injections prescribed (n=720) 
The study found an average of 12.49% (95% CI of 10.1-15.0) of the study population received 
one or more injections (Figure 4.1). This result shows that the overall rate of injection used in the 
four hospitals was lower than the standard requirement of the WHO/Derived Reference Value 
(13.4 – 24.1%). Although there was no significant difference (p= 0.4) found in the use of 
injections across the hospitals, the highest proportion of prescription encounters with an injection 
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was found in PAH (15.6%), followed by UAH (12.8%). PBH and UBH had the lowest 
proportion of injection prescription encounters at 10.6%. 
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Chi-square (X
2
 = 11.7), p= 0.009 
Figure 4.2: Percentage of prescription encounters with antibiotics prescribed (n=720) 
 The study findings on antibiotics utilization showed that just over half (53.7%) of the patient 
encounters resulted in an antibiotic prescription (at 95% confidence interval (CI) (49.9-56.9%) 
compared to 20-27% in WHO/Derived Reference Values (Fig.4.2).  The results showed that 
PBH had the highest rate (62.8%) of patient prescription encounters with antibiotics prescribed 
(p=0.009) while UBH had the lowest rate (46.7%)   
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The statistically significant (p=0.009) difference observed in the prescription encounters with 
antibiotics prescribed across the four facilities indicated that at PBH antibiotics were 
significantly more frequently prescribed to patients than at the other three facilities.  
Table 4.5: Medicines prescribed with generic names (n = 2517) 
Hospital  Number of  Medicines 
Prescribed (n) 
Number of  Medicines 
Prescribed with 
Generic Names  
%  of Medicines 
Prescribed with 
Generic Names 
PAH 658 348 52.9 
PBH 566 311 54.9 
UAH 612 280 45.8 
UBH 681 344 50.5 
OVERALL 2517 1283 50.9 
Chi-square (X
2
) = 16.5, p= 0.0009 
The results of analysis of the use of generic names in the study population are presented on Table 
4.5. It revealed that the average percentage of generic medicines prescribed was 50.9% at (95% 
CI of 45.8-54.9) which is far below the WHO recommendation of (100%). The prescribing of 
medicines with generic names varied from a minimum of 45.8% at UAH to a maximum of 
54.9% observed at PBH. A statistically significant difference (p<0.0009) was found in the use of 
generic medicine names across the hospitals, and UAH was responsible for the observed 
difference by having the lowest propensity to prescribe with generic names. 
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Table 4.6: Medicines prescribed from essential medicines list or formulary (n= 2517) 
Hospital  Number of  Medicines 
Prescribed (n) 
Number of   
Medicines on EML 
%  of Medicines on 
EML 
PAH 658 471 71.6 
PBH 566 445 78.6 
UAH 612 458 74.8 
UBH 681 495 72.7 
OVERALL 2517 1869 74.2 
 Chi-square (X
2
) = 7.7 p= 0.05 
The analysis in terms of medicines prescribed from the EML showed (Table 4.6) that these 
hospitals had between 71.6% - 78.6% of medicines prescribed from the NHIS-EML with no 
significant difference (p =0.05) found among the four hospitals. Overall, 74.2% (at 95% CI, 
71.6-78.6) prescribed medicines were on the EML, suggesting a shortfall of 25.8% compared to 
the WHO target (100%) for this indicator. 
Table 4.7: Summary of overall values (prescribing indicators) compared with Reference 
Standards (n=720) 
Indicators  
n= 
Overall 
Observed 
Values  
WHO/Derived 
Reference 
Values 
p-value 
(p)   
Average No. of  medicines prescribed n=2517 3.5 2 p<0.001 
% of Encounters with an antibiotic 
prescribed. 
n=720 53.2 20 - 27 p=0.009 
% of Encounters with injection 
prescribed 
n=720 12.4 13.4 – 24.1       p=0.4 
% of Medicines prescribed by generic 
name 
n= 2517 50.9 100% p=0.0009 
% of  Medicines prescribed from  EML n= 2517 74.2 100%      p=0.05 
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 Table 4.7 presents a summary of overall study findings on prescription indicators in comparison 
with the WHO/Derived Reference Values. P-values < 5% indicate statistically significant 
difference in prescription of medicines across the hospitals. 
 4.3 Description of Proportion of Medicines Available To Beneficiaries.  
This section describes the extent to which prescribed medicines were available to patients in the 
hospitals under study using a range of indicators.            
Table 4.8: Total medicines dispensed (n = 2517) 
Hospital  Number of  Medicine 
prescribed (n) 
Number of   
Medicines Dispensed 
%  of Medicines 
Dispensed 
PAH 658 625 94.9 
PBH 566 504 89 
UAH 612 487 79.6 
UBH 681 526 77.2 
OVERALL 2517 2142 85.1 
Chi-square (X
2
) = 60.2, p= 0.001 
As can be seen in Table 4.8, the percentages of prescribed medicines actually dispensed in PAH 
(94.9%) and PBH (89.0%) almost correspond to the total number of medicines prescribed. 
Overall, the percentage of prescribed medicines actually dispensed in the study population was 
85.1% at 95% CI (77.2-94.9%) as against 100% targeted by World Health Organization.   
Significant differences (p=0.001) were observed in the values obtained across the hospitals 
which varied from 77.2% (UBH) to a maximum of 94.9% found in PAH. The study found that 
UAH and UBH dispensed lower percentages of prescribed medicines than the remaining two 
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hospitals. It should be noted that the proportion of medicines dispensed consist of both essential 
medicines and those not on the EML.  
Table 4.9: Essential medicines dispensed (n=1869) 
Hospital  Number of Medicines 
Prescribed on  EML 
Number of  Essential 
Medicines Dispensed 
%  of Essential 
Medicines Dispensed 
PAH 471 454 96.3 
PBH 445 432 97 
UAH 458 424 92.5 
UBH 495 434 87.7 
OVERALL 1869 1744 93.4 
Chi-square (x
2
) = 0.129, p= 0.256  
Table 4.9 shows the extent to which prescribed medicines on EML were dispensed relative to 
those prescribed on EML. No statistically significant difference (p= 0.256) was observed in the 
proportion of essential medicines dispensed among the hospitals. However, PBH had the highest 
percentage (97.0%) while the lowest tendency to dispense prescribed essential medicines on 
NHIS-EML was found in UBH (87.7%). Ideally, all prescribed medicines on the NHIS-EML 
should be dispensed; this is nevertheless a reasonable percentage. In this study, the overall 
percentage of prescribed essential medicines dispensed was 93%.  
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 = 109.4), p< 0.001     
Figure 4.3: Percentage of patients having all prescribed medicines dispensed (n=720) 
Further analysis of medicines dispensed was carried out to reveal the proportion of patients who 
had all their medicines dispensed to them across the hospitals (Fig.4.3). Overall, only 58% of 
720 patients‟ prescription encounters had all their prescribed medicines completely dispensed, 
which is far short of the target of 100% access to prescribed medicines envisaged (WHO, 
2004a). 
There was a significant (p<0.0001) difference in number of prescription encounters with all 
prescribed medicines completely dispensed among the hospitals. The study found that the 
propensity of patients having all their medicines completely dispensed was lower in the patients 
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who visited the two urban hospitals, UAH (41%) and UBH (37 %), than those who visited the 
two peri-urban hospitals. Conversely, PAH (82%) had the highest tendency to completely 
dispense all medicines prescribed per prescriptions.  
 
Chi-square (X
2
 = 109.4), p< 0.001 
Figure 4.4: Utilization rate of referral/reimbursement process (n=720) 
Ideally, a secondary public sector hospital with an in-house pharmacy should ensure that all 
prescribed essential medicines are dispensed to patients by releasing unfilled prescriptions to 
accredited pharmacies outside the hospitals and thereafter reimbursing the cost of the medicines 
dispensed to the patients to the referred pharmacy. Where the cost of the prescription was paid 
by the patient, then reimbursement should be made directly to the patient. Figure 4.4 shows the 
utilization rate of the process of referring patients‟ prescriptions to accredited pharmacies and 
reimbursement of out-of-pocket expenditures on prescribed essential medicines.  
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The study found that UBH (63%) had the highest number of patients‟ prescription encounters 
with prescribed medicines not completely dispensed, while the lowest was observed at PAH 
(18%). Overall, 42% of the 720 patients did not have all their prescribed medicines completely 
dispensed. It was observed that none of the hospitals referred or reimbursed patients for out-of-
pocket expenditure on prescribed medicines covered by the scheme.  
Table 4.10: Summary of Medicines Received by Insured Patients  
Indicators  Overall Observed 
Value 
 Ideal Value  p-value (p)   
% of overall medicines dispensed 85.1 100% p= 0.001 
% of EMs dispensed relative to 
medicines prescribed on EML. 
93 100% p= 0.256 
% of prescriptions with all prescribed 
medicines completely dispensed. 
58% 100% p< 0.001 
 
Table 4.10 summarises the dispensing of prescribed medicines to patients in the study.  A p-
value < 5% indicates statistically significant difference in the dispensing of prescribed medicines 
across the hospitals. 
 
 
 
 
 
  
 
 
 
 
 66 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 4
.1
1
: 
S
u
m
m
a
ry
 o
f 
R
es
u
lt
s 
%
 
 
o
f 
M
ed
ic
in
es
 
R
ef
er
re
d
 
0
 
0
 
0
 
0
 
0
 
    1
0
0
%
 
L
eg
en
d
: 
P
X
N
 =
P
re
sc
ri
p
ti
o
n
s 
%
 
 
o
f 
P
re
sc
r
ib
ed
 
E
m
s 
D
is
p
en
se
d
 
9
6
.3
 
9
7
 
9
2
.5
 
8
7
.7
 
9
3
.4
 
    1
0
0
%
 
%
 
 
o
f 
 
P
X
N
s 
 
co
m
p
le
te
ly
 
D
is
p
en
se
d
 
8
2
 
7
1
 
4
1
 
3
7
 
5
8
 
    1
0
0
%
 
%
 
 
o
f 
 
T
o
ta
l 
M
ed
ic
in
es
 
D
is
p
en
se
d
 
9
4
.9
 
8
9
 
7
9
.6
 
7
7
.2
 
8
5
.1
 
    1
0
0
%
 
%
 
 
o
f 
 
M
ed
ic
in
es
 
o
n
 
E
M
L
 
7
1
.6
 
7
8
.6
 
7
4
.8
 
7
2
.7
 
7
4
.2
 
    1
0
0
%
 
%
 
 
o
f 
G
en
er
ic
s 
M
ed
ic
in
es
 
P
re
sc
r
ib
ed
 
5
2
.9
 
5
4
.9
 
4
5
.8
 
5
0
.5
 
5
0
.9
 
    1
0
0
%
 
%
  
 o
f 
 P
X
N
s 
w
it
h
 
A
n
ti
b
io
ti
cs
 
5
5
 
6
2
.8
 
4
8
.3
 
4
6
.7
 
5
3
.7
 
    2
0
.0
 –
 2
5
.4
 %
  
 
%
  
o
f 
P
X
N
s 
 
w
it
h
 
In
je
ct
io
n
s 
1
2
.4
 
1
0
.6
 
1
2
.8
 
1
0
.6
 
1
5
.6
 
    1
0
.1
 –
 1
7
.0
%
  
 
A
v
er
a
g
e 
o
f 
M
ed
ic
in
es
 
P
re
sc
r
ib
ed
 
3
.7
 ±
 1
 
3
.1
 ±
 1
 
3
.4
 ±
 1
 
3
.8
  
±
 1
 
3
.5
 ±
1
 
1
 
6
 
1
.6
 -
 1
.8
 
H
o
sp
. 
P
A
H
 
P
B
H
 
U
A
H
 
U
B
H
 
O
V
E
R
 A
L
L
 
M
in
. 
 
M
a
x
. 
 
W
H
O
/D
er
iv
ed
 
R
ef
er
en
ce
 
V
a
lu
es
 
(i
d
ea
l 
V
a
lu
es
) 
 
 
 
 
 67 | P a g e  
 
4.4 Summary 
Table 4.11 summarises the findings for the main study variables in each of the four hospitals and 
overall, together in a comparison with the WHO/Derived Reference Values. The results found 
that 720 prescription records sampled for study contained 2517 prescribed medicines.  
The overall average number of medicines prescribed per prescription encounter was 3.5 ±1 (p< 
0.001). Injections were prescribed in 15.6 (p= 0.4) of the encounters, while more than half, 
53.7% (p=0.009) contained at least one antibiotic.  Overall, 50.9% (p<0.0009) of the medicines 
were prescribed by generic names while 74.2% (p=0.05) of prescribed medicines were from the 
EML. 
The study also found that 85.1% (p=0.001) of overall prescribed medicines were dispensed by 
on-site pharmacies, specifically, out of the total essential medicines prescribed, 93.4% (p= 0.256) 
was dispensed. Overall, only 58% (p<0.0001) of 720 patients‟ prescription encounters had all 
prescribed medicines completely dispensed. 
In conclusion, the results of this study were considerably different to the WHO/Derived 
Reference Values.  The appropriateness of prescribing and the implications of these results on 
access to health care and health outcome in the National Health Insurance Programme will be 
discussed in the next chapter.  
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CHAPTER FIVE 
DISCUSSION 
 
5.0 Introduction 
The Social Health Insurance Programme was introduced in Nigeria to provide quality and 
accessible health care to all Nigerians at an affordable cost. Since its inception in June 2005, 
there is no information on prescribing practices or the availability of medicines to insured 
consumers. This study attempted to investigate prescribing practices as well as availability of 
medicines in accredited public sector secondary hospitals in the Federal Capital Territory, 
Nigeria between July 2009 and June 2010.  
This chapter presents the interpretation of the findings of this study, compares the results with 
previous studies and discusses the implications of the trends in prescription patterns and 
availability of essential medicines in this setting.  
5.1 Description of Prescribing practices  
The findings of the study revealed considerable irrational prescribing practices in the form of 
poly-pharmacy, overuse of antibiotics, as well as poor use of generic medicines and those on 
EML. However, injections were found to be prescribed within the optimal range provided by the 
Reference Values. The detailed results of the prescription indicators and their implications are 
discussed below. 
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5.1.1 Tendency to Poly-pharmacy 
5.1.1.1 Categories of Medicines Prescribed  
The analysis of data on the categories of medicines prescribed revealed the predominance of 
anti-infective agents, analgesics/NSAID and vitamins/haematinics amongst the top ten categories 
of medicines prescribed at all the hospitals. They accounted for 67.4% of the medicines 
prescribed in the overall study population (Table 4.4). These findings are consistent with those 
reported in previous studies by Akande and Ologe (2007).  
 
The high proportion of prescribed anti-infective agents (40.3%) observed in the overall study 
population correlates with the prevalence of infectious and parasitic diseases in the study area 
(FCT Health Report, 2006; WHO, 2007c). The rationale for the high proportion of 
vitamins/haematinics (9.4%-16.2%) is outside the scope of this study; however, studies have 
shown that they have little or no medical importance except where anaemia is suspected. 
Evidence has shown that these categories of medicines are often abused by prescribers who use 
them to gratify patients‟ desire for medicines and this could be a possibility in this setting too 
(Neyaz, et al., 2011).  
5.1.1.2   Average Number of Prescribed Medicines  
A breakdown of the number of medicines prescribed per encounter found that 80% of the overall 
prescription encounters contained three or more medicines (Table 4.2), while the overall average 
number of prescribed medicines per encounter, 3.5 SD ±1 (Table 4.3), exceeds the range 
recommended in the WHO/Derived Reference Values (1.5-1.8) and the average (1.3-2.3) 
reported in research conducted in some developing countries (Hogerzeil, and Ross-Degnan, 
2001). These values indicate a high tendency towards polypharmacy in providers‟ prescribing 
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practices. Possible reasons for the observed polypharmacy could be due to demands from 
patients as reported in a study conducted in China where it was shown that insured patients are 
more likely to demand for certain types of medicines including painkillers, antibiotics and 
vitamins (Moreira, et al., 2006). Similarly, the high use of anti-infective agents, multivitamins 
and analgesics/ (NSAID) (32.5%) as observed in this study (Table 4.4) could have likely 
contributed to the high averages observed in this study. These results are consistent with findings 
in other countries that health insurance tends to increase medicine utilization (Moreira et al, 
2006). 
Poly-pharmacy and unnecessary prescription of medicines have serious potentially economic and 
health implications for social health insurance programmnes. First, poly-pharmacy and 
unnecessary use of vitamins, tonics, antibiotics and adjuvants may cumulatively increase the 
expenditure on medicines and the cost of co-payments paid on prescribed medicines. Studies on 
the RAND health insurance experiment showed that hhigh co-payment on services may deter the 
vulnerable and low income earners from accessing basic services which may invariably result in 
poor health outcomes (Leighton 1996; Hudman and Molly, 2003; EDM, 2003; Goldman, Joyce 
and Zheng, 2007; Lu, et al., 2008). In addition, high co-payments exert financial constraints on 
government funding of the scheme. For example, the US Centre for Medicare and Medicaid 
Services reported that the USA spends US$50 billion annually on polypharmacy on the nation‟s 
health care plan (Bushardt, et al., 2008). Such financial cost may be unaffordable in Nigeria, 
particularly in view of the report that the scheme is grossly underfunded (Anyene, 2011). In 
addition, these patients are more likely to be hospitalized in the event of medicine toxicity and 
antimicrobial resistance, resulting from irrational prescribing (Moreira et al, 2006). 
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Second, the current study also found that 81.1% of the study population had three or more 
medicines prescribed suggesting that at least large numbers of patients were exposed to the risks 
of medicines toxicity resulting from adverse reactions and poor patient compliance, which are 
associated with a high pill burden. Of particular concern are people living with HIV/AIDS who 
are at high risk of adverse medicine reactions as a result the burden of antiretrovirals (ARVs) and 
other regimen used in control and treatment of HIV/AIDS (Clarke et al. 2008; Seden et al., 
2009). The side effects and economic burden of purchasing ARVs combinations as well as the 
inconveniences of the dosage regimen tend reduce adherence rate in people living with 
HIV/AIDS (UNAIDS, 2008; Clarke et al. 2008).  
 5.1.2. Injections Prescribed  
In this study, the overall rate of injections (10.5% in Fig. 4.1), is within the optimal range in the 
WHO/Derived Reference Values (10.1-17.1). This should be lauded. A comparison of this result 
with findings from previous studies conducted in Nigeria indicates that there is a decline in the 
use of injection (Ugochukwu, Onwujekwe and Akpala, 2002; Akande and Ologe, 2007). The 
decline could be attributed to the positive impact of government interventions which has 
increased prescribers and members of the public awareness of the risks associated with 
unnecessary use of injections. For instance, the compliance of prescribers with the policy change 
from chloroquine to artemisinin-based combined therapy (ACT) for treatment of malaria could 
have drastically reduced the use of chloroquine injection (FMOH, 2010b).  
5.1.3   Use of Antibiotics  
The overall percentage of patients receiving antibiotics (53.7% in Fig. 4.2) was found to be unacceptably 
high when compared with the recommendation in the WHO/Derived Reference Values which ranged 
from 20-24%.  A slightly lower value of 51.0% was reported in a study recently conducted in similar 
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settings by Ehijie and Chima (2011). Comparison with findings from other countries shows that the use of 
antibiotics in this study is higher than the values (50%) reported in Nepal, but lower than the value 
(68.1%) was reported by Mohlala,
 
et al., (2010) in South Africa. 
The high utilization of antibiotics observed in this study could be attributed to the prevalence of 
communicable diseases in Nigeria and inadequate knowledge of prescribers on appropriate use of 
antibiotics (WHO, 2002; WHO, 2007c; Oshikoya, Senbanjo and Sodipe, 2009). Previous studies in 
Nigeria have shown that a substantial proportion of antibiotics prescribed for outpatients in public health 
facilities were for prophylaxis, diseases of non-bacterial aetiology like cough and fever, and other 
presumed diseases without sufficient diagnosis (Odunsanya, 2004; Nwolisa, Erinuagha and Ofoleta 2006;
 
Onwujekwe,  et al., 2009; Erah and Ehiagwina, 2010; Oshikoya and Senbanjo, 2010).   
Given the importance of antibiotics in combating infectious diseases in high-burdened countries 
like Nigeria, the irrational use of antibiotics observed in this study has the tendency to reduce the 
therapeutic effectiveness of antibiotics as a result of emergence of bacterial resistance to 
antibiotics; this predisposes patients to the risk of treatment failure. The consequences are higher 
with people living with HIV/AIDS seeing that they need to take antibiotics daily to prevent or 
treat HIV-related opportunistic infections. This may necessitate switching to more expensive 
antibiotics in the process of treating resistant strains (Pavin, et al., 2003; Holloway, 2004; 2005; 
Erah and Ehiagwina, 2010). Available evidence has shown that antibiotic-resistant infections are 
the principal cause of death in AIDS (UNAIDS, 2008). 
5.1.4 Generic Prescription 
Previous studies conducted to determine the rate of generic prescription in Nigeria have reported 
values in the range of 37.0-54.8%, which are considerably lower than the suggested target of 
100% by the WHO (Hogerzeil; 2000; Erah, Olumide and Okhamafe, 2003; WHO, 2004a; 
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Akande and Ologe, 2007; Adebayo and Hussain 2010; Enato and Chima, 2011). In this study, 
only 50.9% (Table 4.5) of the total medicines prescribed were written in their generic names. 
This value is lower than those obtained in health insurance programmes of China and Iran (Sun, 
et al., 2009; WHO, 2009d). The low percentage of generic medicines indicates high use of 
branded medicines which is likely to be due to the influence of pharmaceutical marketers; and 
poor perception of the safety and quality of generic medicines by physicians (Holloway, 2000; 
King and Kanavos, 2002; Ijoma, et al, 2010: Leo and Okafor, 2012). 
Other studies have also shown that the preference for branded products could be attributed to 
providers‟ perceptions that generic names are unattractive and difficult to remember,  and the 
profit margin and demand for  generic medicines are low (Abdelmoneim, Tayeb and Omer, 
1999; Chen , et al., 2011).  
Notwithstanding the reasons given for the poor use of generic medicines, unnecessary use of 
expensive branded medicines will led to the depletion the capitation that could have been used to 
procure more of clinically equivalent generic medicines for wider coverage of insured patients 
(Hogerzeil, 2004). In addition, the provision of branded products to insured patients may result 
in higher co-payments, which can disproportionately affect low income earners (Chen, et al., 
2011). Patients may also resort to purchasing prescribed branded medicines on their own when 
health facilities are not sufficiently stocked to dispense the generic equivalents listed on the 
EML. In particular, there is a high tendency that the health outcome of low income earners who 
may not have the financial means to purchase prescribed branded products will be affected 
negatively (Adebayo and Hussain, 2010; Chen, et al., 2011). The use of brand products in a 
social health insurance programme is therefore inappropriate and ineffective in ensuring 
availability of medicines and equal access to cost effective essential medicines.  
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5.1.5 Medicines Prescribed on Essential Medicine List 
Good use of the EML will to an extent, determine which prescribed medicines will be dispensed 
to insured patients. Ideally, all prescribed medicines should be on the NHIS-EML to facilitate 
access to the required ones. However, evaluation of the extent of physician adherence to the 
NHIS-EML found that the range of the percentage (71.6-78.6%: Table 4.6), of medicines 
prescribed from the NHIS-EML was significantly lower than 100% recommended by the WHO. 
Higher values ranging between 82-97% were reported in previous studies conducted in other 
parts of the country a few years earlier (Akoria and Isah 2001; FMOH/WHO 2002; Ugochukwu, 
Onwujekwe and Akpala, 2002). The comparison of these results with those from other 
developing countries found that higher values were obtained in Zimbabwe 100%, (WHO, 2004a) 
and Ghana 97% (Bosu and Ofori-Adjei 2000). Further investigation is suggested to elucidate on 
the observed decline in the use of medicines on the EML in a social health insurance setting.  
 
The study also observed that the percentages of medicines prescribed on the NHIS-EML in all 
the hospitals, 71.6-78.6% are relatively higher than the corresponding percentages of medicines 
prescribed in generic names. This suggests that a significant proportion of prescribed branded 
products have their generic equivalent in the NHIS-EML. This pattern of prescription is grossly 
irrational as patients would likely pay higher co-payments on prescribed brand products which 
have generic equivalents listed in the NHIS-EML. Equity in health insurance would require an 
increased utilization of generic essential medicines to ensure effective use of scarce resources in 
providing access to all. Therefore, the low prescription of medicines on the EML strongly 
suggests a negative impact on equity in access to health care. 
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Poor availability of EML in public health facilities has been cited as one of the reasons for poor 
use of medicines on the EML (Chedi, Abdu-Aguye and Kwanashie 2010). However, some 
studies have shown that even when copies of the EML are available, some prescribers still rely 
on proprietary reference books and advertisements in medical journals, which are inadequate 
sources of information needed for appropriate prescribing (Akande and  Aderibigbe, 2007; 
Oshikoya, Senbanjo and Sodipe, 2009; Adebayo and Hussain, 2010). 
The poor use of medicines on the EML observed in this study could also be attributed to the 
delay in updating national EML and NHIS- Formulary. Available information suggests that some 
countries like Nigeria do not comply with the WHO recommendation that countries should 
update their national EML regularly (Akter, et al., 2012). 
After seven years of the usage of its 2003 fourth edition of the national EML, Nigeria published 
its current edition (Fifth Edition) in October, 2010. The fifth edition contains Artemisinin 
Combination Therapy in line with the current malaria treatment policy, and other WHO 
therapeutic options for treatment of emerging diseases. On the other hand, the current NHIS-
Medicines Formulary and treatment guidelines which were based on the fourth edition (2003) of 
the national EML is yet to be updated to incorporate newer medicines listed in the fifth edition.   
These could have promoted the prescription of medicines particularly antimalarials that are not 
listed in the NHIS-Formulary.  
5.2 Availability of prescribed medicines to insured patients 
The finding with regards to availability of medicines for health insurance patients are described 
with the following indicators: percentage of total medicines dispensed, percentage of essential 
medicines dispensed and the proportion of patients having all prescribed medicines dispensed. 
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5.2.1. Aggregate Medicines Actually Dispensed in Study Hospitals 
A high percentage of prescribed medicines were actually dispensed 85% (Table 4.8) to insured 
patients at the study facilities‟ pharmacies. This result is consistent with the general belief that 
health insurance schemes are associated with increased percentages of prescribed medicine 
actually dispensed (Frenk, Gomez-Dantes and Knaul, 2009). However, the result is lower than 
100% suggested by WHO and the value (87%) obtained in the surveys conducted in 1982-2006 
in some Sub-Saharan Africa countries WHO (2009a). 
Nevertheless, the result suggests a slight improvement on the values reported by Tetteh and 
Adeya (2005) in a study conducted to assess the availability and use of antimalarial medicines in 
some public hospitals in Nigeria. The result is an indication that there was adequate supply of 
various medicines in the study facilities. Other possible reasons for these improved figures could 
be that prescribers were better informed of the type of medicines in stock and consequently 
prescribed accordingly (Holloway, 2000).  
5.2.2 Essential Medicines Dispensed 
An important finding in this survey is that only 87% of prescribed essential medicines were 
dispensed to patients (Tables 4.9). Ideally, all prescribed essential medicines should be 
dispensed. The shortfall in the proportion of prescribed essential medicines dispensed could be 
an indication of inadequate stocks of essential medicines recommended in the NHIS-medicines 
formulary. Another possible reason that could explain the sub-optimal proportion of prescribed 
essential medicines dispensed is insufficient funding of the scheme. According to Onwuka, 
(2008) allocations from the pool of employers‟ contributions for health insurance falls short from 
the amount needed to meet the aspirations of the population. Thus if complete access to 
recommended essential medicines is to be achieved, additional funding may be required. It 
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should be noted that currently, federal civil servants who are major beneficiaries of the FS-SHIP 
are yet to contribute their 5% shares to the scheme (Ogundipe, 2009). One way of improving on 
funding is to expedite action on commencing the deduction of employees‟ contribution (5% of 
basic salaries) to the scheme.  
5.2.3. Proportion of Patients Having All Prescribed Medicines Dispensed 
Although the percentage of prescribed medicines dispensed to patients provides an indication 
that a large proportion of the products are dispensed to patients, further analysis showed that the 
medicines were not equitably available to all the patients as only 58% (Figure 3) of the insured 
patients had all their prescribed medicines completely dispensed, while the remaining 42% had at 
least one prescribed medicines not dispensed.  
Possible reasons for this poor performance could partly be due to prescription of medicines 
outside the benefit coverage or non-compliance of the study facilities to refer patients to 
accredited pharmacies outside the study facilities.    
There is a tendency that medicines not dispensed included essential medicines, and their non-
availability, therefore, constituted access barrier to quality health services. This implies that the 
affected patients (42%) would have to bear the financial burden of purchasing such medicines on 
their own (Pavin, et al., 2003). Studies have shown that patients‟ whose prescriptions are not 
completely dispensed, are three times more likely to purchase less than the required quantity of 
medicines prescribed (Saradamma, Higginbotham and Nichter, 2000). In this scenario, 
disproportionately affected low income earners may resort to borrowing to purchase the 
medicines which may further impoverish the households‟ income or may completely forego 
treatment, thereby worsening their ailments (OECD/WHO, 2003b; Pavin, et al., 2003). 
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5.2.4   Prescriptions Referred and Dispensed in Accredited Off-site Pharmacies: 
Evidence from Taiwan suggests that compliance with the principle of the SPD policy, which 
requires the release of prescriptions by providers to accredited private pharmacies, resulted in 
more rational prescribing and a significant decrease in expenditure on medicines (Faden, et al., 
2011). Similarly in the NHIS programme, the extent to which prescribed medicines are provided 
to insured patients is dependent on the ability to have all prescribed medicines dispensed in the 
accredited pharmacy unit of hospitals visited by patients or accredited off-site pharmacy when 
prescriptions are released to them. 
The result of this study showed that none of the study facilities released their prescriptions to 
accredited private pharmacies when the pharmacy units could not provide all prescribed 
medicines to the insured patients (Figure 4). This implies that insured patients were left to source 
unavailable prescribed essential medicines on their own. This invariably shifted the cost of 
prescribed essential medicines to patients. 
Considering the overall proportion of patients without essential medicines, referring them to 
accredited private pharmacies would have increased the number of patients having access to all 
prescribed EMS, improving their health outcomes and reducing the economic hardship of 
sourcing medicines on their own (Pavin, et al., 2003).  
The non-referral of these patients also exposed them to the risk of purchasing poor quality 
medicines from non-professional medicine dealers and denied them the opportunity to access 
standard dispensing practices and other pharmaceutical services offered freely by professional 
Pharmacists in accredited pharmacies (FMOH, 2005a). This is inconsistent with the objectives of 
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the scheme as ensuring compliance of providers to release prescriptions to pharmacies to 
dispense is an important policy directive. 
5.3 Implications of Irrational Prescribing and Poor Availability of Medicines 
The irrational prescription and poor availability of medicines found in this study have several 
implications on providers, in this case the SHIP and patients. 
5.3.1 Implications for Providers  
According to King and Kanavos, (2002), efficient allocation of health insurance funds is 
achieved with rational prescribing of available medicines. Given that health insurance systems 
are characterized with fix tariffs for recommended medicines and capitation of services,  the use 
of brand medicines, overuse of antibiotics, low use of generic medicines and polypharmacy as 
observed in this study, likely increase providers‟ expenditure on medicines and may result in 
short falls on the capitation received (WHO, 2010). This will invariably make the scheme 
unprofitable and unsustainable for the health providers (Dong, et al., 1999; Mills, et al., 2005).  
5.3.2 Implications for Patients  
It is widely acknowledged that consumers place a high value on availability of medicines and it 
has been shown to increase patient satisfaction and confidence in the health care system (Faden, 
et al., 2011). The findings of this study with regards to poor availability of prescribed essential 
medicines, the possibility of high co-payments and the burden of out-of-pocket payments for 
unavailable products without re-imbursement, suggest that patients may lose confidence in the 
scheme‟s potential to meet their medicines needs (Kreling, 2000; WHO, 2009a). In addition, the 
heavy out-of-pocket expenditure on medicines which the scheme promised to address, is still in 
existence as a high proportion of patients (42%) were left to access unavailable prescribed 
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medicines without any recourse to re-imbursing them. This observation was similarly reported 
by Awe and Sanusi (2009) where 80% of people sampled had no confidence in the scheme due 
to unnecessary payment for medicines and services already covered by capitation.  
5. 3 Limitations of Study 
The current study only describes irrational prescribing practices amongst the sampled hospitals; 
the cross-sectional design used in this study does not permit the detection of aetiological reasons 
for prescribing (Grimmes and Schuz, 2002).  
Also, availability of medicines was measured based on medicines received by patients without 
giving prominence to other contextual factors that could have affected the extent to which 
prescribed medicines are dispensed to insured patients. In spite of these limitations, this study 
provides the baseline data for further research to facilitate intervention needed to promote 
rational prescribing and availability of essential medicines in the social health insurance system 
in Nigeria. In addition, as the first study on prescribing practices and availability of medicines in 
the National Health Insurance Scheme in Nigeria, the study has contributed to knowledge on 
prescribing practices and access to essential medicines in health insurance programmes in 
developing countries by explicitly focusing on only the prescription encounter records of insured 
outpatients. 
5.4 Summary 
The findings of this study when compared with the WHO/Derived reference values shows that 
the prescribing practices in the social health insurance scheme programs of the study facilities 
were characterized by poly-pharmacy, overuse of antibiotics, low use of generic medicines, and 
suboptimal use of medicines on NHIS-medicines formulary. Inadequate provision of prescribed 
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essential medicines was evident in all the study facilities. The policy recommendation for 
improving rational prescribing and availability of prescribed essential medicines will be 
discussed in the next chapter. 
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CHAPTER SIX 
CONCLUSION AND RECOMMENDATIONS 
 
6.0. Introduction  
This chapter draws conclusions on the findings of this study, in relation to standard measures of 
rational prescription and availability of medicines, and the implications for the Social Health 
Insurance Programme operational in public sector secondary hospitals in the Federal Capital 
Territory, Nigeria. This chapter concludes with recommendations for policy considerations.  
 6.1 Conclusion 
The findings of this study show trends towards irrational prescribing practices as characterized 
by poly-pharmacy, over use of antibiotics, sub-optimal generic prescribing as well as poor 
adherence to the use of the NHIS-EML. However, the use of injections was found to be 
appropriate, which is laudable. This indicates that the National Health Insurance Scheme has not 
achieved good prescribing practices in this study population. These findings are in line with the 
growing body of evidence of existence of inappropriate prescribing practices in health insurance 
programmes that are not adequately monitored (Bruntland, 2003).  
This study also provides evidence that many insured patients (42%) in the study settings did not 
have all their prescribed medicines dispensed. There was sub-optimal provision of essential 
medicines and prescriptions were not referred to accredited private pharmacies, signifying access 
barriers to essential medicines and pharmaceutical care. This is a pointer to inadequacy in the 
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scheme‟s ability to ensure compliance to its operational guidelines and to actualize its objectives 
of equity in access to essential medicines. 
The prescribing practices and the inequity in access to prescribed medicines as observed in this 
study constitute a threat to the scheme‟s goal of achieving universal access to health care in the 
year 2015. Pragmatic interventions should be deployed towards promoting rational prescribing as 
well as increasing equity in access to essential medicines. 
6.2     Recommendations  
In the light of the findings of this study, the following recommendations are suggested to 
improve the quality of prescribing and increase access to prescribed medicines in the SHIP. 
1) Training on rational use of medicines 
a) Providing regular training for all health personnel with an emphasis on the importance of 
rational use of medicines and appropriate use of the NHIS approved formulary.  
b) Regular dissemination of the NHIS operational guidelines, NHIS price list and NHIS 
treatment protocols to all prescribers and dispensers.  
2) Monitor medicines utilization patterns 
a) Evaluating data reported by providers to identify medicines use problems and opportunities 
for interventions.  
b) Regular supervision and monitoring of dispensing practices to ensure compliance with the 
standard specifications for provision of prescribed essential medicines to insured patients. 
c) Enforcing compliance with standard specifications for dispensing by removing non-compliant 
providers from participation in the scheme.  
 
 
 
 
 84 | P a g e  
 
3) Ensure Sustainable Availability and Access to Essential Medicines 
a) Strengthening the HMOs to effectively supervise and monitor pharmaceutical procurement 
and management activities to ensure uninterrupted supply and availability of essential medicines 
at health facilities.  
b) Updating the NHIS medicine formulary and treatment guidelines to harmonize with the 
current 5
th
 edition (2010) of the national EML.  
c) Increasing the sources of funding including the commencement of payment of beneficiaries 
(federal civil servants) contributions (5% of employee basic salary) to the scheme. 
4) Public Awareness 
Increase public awareness on the benefits of health insurance, consumers‟ right to                            
essential medicines and the dangers of irrational use of medicines. 
5)  Areas of Further Research  
a} Research is required to explore the impact of morbidity patterns on prescribing practices of 
prescribers attending to insured patients in the study hospitals in order to identify appropriate 
interventions for promoting rational prescribing.  
b) Research is also required to understand additional contextual factors that could constitute 
access barriers to medicines in the study hospitals and to identify appropriate interventions for 
increasing availability and access to essential medicines.  
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APPENDICES 
Appendix-1  
Nigeria’s health and socioeconomic indicators 
INDICATORS ESTIMATE 
Demographic Indicators  
Total population  (2001)  155,215,573 
Annual growth rate  3.2% 
Urban population  50% 
Socio-economic Indicators  
Gross Domestic Product (GDP) per capita  $ 2,500 
Total expenditure on health as a percentage of the GDP  
(2000)  
5.8% 
Population below poverty line (CIA, 2007 est.)  70% 
Gross national income per capita (PPP international $) 1,980 
Total expenditure on health per capita (Intl $, 2009) 136 
Total expenditure on health as % of GDP (2009) 5.8 
Health Structure  
Physician density  physicians/ 1,000 population (2008) 0.395 
Hospital bed density/1000 population (2004 estimate) 0.53 
 Health Status Indicators  
Life expectancy at birth for males 53 
Life expectancy at birth for females  54 
Under 5 Mortality Rate (per 1,000 children) 138 
People living with HIV/AIDS  3.4Million 
Sources: Nigeria demographic and health survey 2010, CIA 2009, Human Development Report 
2010,  Federal Ministry of Health, Report (2010)  and WHO, 2009b Report. 
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Appendix 2:  
Programmes Categories of National Health Insurance Scheme 
A1)  Formal Sector Health Insurance Programme 
 Federal Civil Service Social Health Insurance Programme(FS- SHIP) 
 Organized private sector Social Health Insurance Programme (OPS-SHIP) 
 Armed forces, police and allied services Social Health Insurance Programme 
 Students of tertiary institution Social Health Insurance Programme( TI-SHIP) 
 Voluntary contributors: These are interested individuals such as Retires (who wish to continue 
with the NHIS formal sector programme), Nigerian‟s in Diasporal, employees with less than ten 
(10) employees or self employed persons. 
 
A2)   Informal Sector Social Health Insurance Programmes 
These include: 
 Rural Community Social Health Insurance Programme  
 Urban self employed Social Health Insurance Programme 
 Vulnerable group Social Health Insurance Programme 
 Children Under-Five Social Health Insurance Programme 
  Prison Inmates Social Health Insurance Programme 
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Appendix-3:   
Transfer of National Health Insurance Funds From N.H.I.S. To Providers 
 
                                                        
 
 
  
 
 
                                  
 
  
                                                                               
Primary Providers                                                                                                           
          Specialist Hospitals 
          Pharmacies 
          Dentistry 
          Laboratories 
          Physiotherapies 
          Radiography centre 
(FMOH, 2005a) 
 
 
          HMO 
CAPITATION 
CASE PAYMENT    
 NHIS (ADMIN 
COST)   
FEEE-FOR- SERVICE 
RESERVE FUNDS 
(Security Fund) for  
Equalization 
 
        NHIF 
Secondary Providers   
   Tertiary Providers 
        CONTRIBUTIONS (GOVT. PUBLIC SECTOR) 
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Appendix 4  
Data Compilation Form 1 
Facility (coded name):  ____________________________________________                     
Investigator:  ________________________________________  
Month of Investigation_____________________________________ 
 
  
 
 
 
 
 
 
 
Serial 
Nos   
Date  of 
prescription  
Code  for 
Patient’s 
Name 
NHIS 
Code 
Names of 
Medicines 
prescribed 
Route of   
administration 
Number of 
medicines  
Dispensed  
Number of 
medicines  
Referred  
1 
  
 1) 
2) 
3) 
   
2 
       
…15  
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 Appendix 6 
 
 Facility Summary Form 
 
Date: ____________ 
 
 
 
 
 
 
 
 
 
 
 
Hosp. Average of 
Medicines 
Prescribed 
%  with 
Injections 
%  with 
Antibiotic  
% 
Generics 
Medicines 
%  of  
Medicines 
on EML 
%  of  
Total 
Medicines 
Dispensed 
%  of  
Prescribe
d EMs 
Dispensed 
%  of  
Prescriptions  
Completely 
dispensed 
%  of 
Medicines 
Referred 
PAH                  
PBH                  
UAH                  
UBH                  
OVER 
ALL 
                 
Min.    
Max.    
 
 
 
 
 110 | P a g e  
 
 
Appendix 7 
 
Data Collection Guidelines  
1. Medicines classified as antibiotics were medicines classified as antibiotic on NHIS 
Essential Medicines List. 
2. Injections used for vaccination and family planning were excluded from being measured 
in this research. 
3. Prescribed brand products which have their generic equivalent in the EML was regarded 
as medicines prescribed from the EML. 
4. A product comprising of two or more medicines for instance multivitamins, were 
considered as one. 
5. All suspensions or tablets prescribed concurrently with the injection components, such as 
a prescription containing paracetamol tablets and suspension together; were considered as 
a single entity and counted and recorded as one in the data compilation sheet. 
6. Measurement of generic name indicator was based on the name used in the prescription 
and not the names of the product dispensed. 
7. Abbreviated names of generic medicines commonly used by prescribers in Nigeria were 
counted as generic medicines during the data analysis process.  
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Appendix 8 
 
Common Abbreviations used in prescribing medicines 
 
GENERIC MEDICINE IN NHIS-EML  COMMON NAMES OR ABBREVIATION 
Paracetamol PCM, P/cmol 
Multivitamin tab M/Vt  M/Vite 
Vitamin B Complex B.Co, Vit-BCO 
Vitamin C or Ascorbic acid Vit-C 
Acetyl Salicylic Acid ASA 
Mist. Magnesium Trisilicate MMT 
Cough Expectorant Elixir Cough Syrup 
Tetracycline Cap TCN 
Ciprofloxacin Cipro 
Amoxycillin Amoxyl 
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Appendix 9 
 
 ETHICAL APPROVAL LETTER 
 
 
 
 
 
 
 
 
